China Pharmaceutical Guide


Written by:

James J. Shen, MBA

Unrivaled China Healthcare Intelligence Since 1991
Published by WiCON International Group

WiCON International Group LLC
311 Sayre Drive, Princeton, NJ 08540, USA
Tel: +1 609 903 8881   Fax: +1 702 995 3905
Email: info@pharmachinaonline.com   Internet: www.pharmachinaonline.com

China Office
Suite 17D, Building B, Oriental Kenzo Plaza
48 Dongzhimenwai Dajie, Dongcheng District, Beijing 100027, China
Tel: +86 10 8447 6010   Fax: +86 10 8447 6110
Email: info@pharmachinaonline.com

Disclaimer
While every effort has been made to ensure that information in this publication is correct, no liability can be accepted for any loss incurred in any way whatsoever by any company or individual relying on the information herein. To the best of our knowledge the information given is accurate at the date of publication.

Copyright © 2016 by WiCON International Group LLC
All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means – electronic magnetic tape, mechanical, photocopying, recording or otherwise – without prior permission of the copyright owner.
ABOUT THE AUTHOR / PUBLISHER

China Pharmaceutical Guide is authored, edited and published by James J. Shen, a veteran of the Chinese healthcare industry and market, who has dedicated his entire 29-year career to pharmaceutical businesses in China.

James Shen has rich operational and senior level management experience on China's healthcare businesses in the capacities of a senior consultant to multinational pharmaceutical companies, a manager of joint venture projects and companies, a business development executive, an entrepreneur, and most recently a publisher.

James Shen started his career in the pharmaceutical industry in 1987 when he joined Beijing Ciba-Geigy Pharmaceutical Ltd. (now Beijing Novartis) as Assistant to the General Manager. While he studied MBA in England in various periods of 1980s, he worked as an editorial consultant for Scrip/PJB Publications, IMS and Financial Times Business Information on China’s healthcare news.

In 1991, he founded WiCON International Group in the USA to provide strategic consulting and competitive intelligence to international healthcare companies in order to assist and facilitate their market entry into China. He has worked with many large and mid-size international pharmaceutical companies on a diverse range of projects including entry strategy development, strategic alliances and joint ventures, marketing and distribution agreements, product registration and clinical trials, licensing and technology transfer, API sourcing, and M&A due diligence.

As an entrepreneur, James Shen co-founded Beijing Jicai Pharmaceutical Technologies Ltd. in 1992, one of the first private pharmaceutical research institutions in China, and took over its management in 2001. He is also a co-founder of Nanjing Zinox Pharmaceutical Co. Ltd., an emerging generic pharmaceutical company in China.

James Shen was the Managing Editor of the well-known IMS China Update, a monthly newsletter covering China's pharmaceutical market co-published by IMS and WiCON. He authored many China healthcare business publications in English throughout 1990s, including Marketing Pharmaceuticals in China, Guide to Pharmaceutical Research Institutions in China, and Directory of Bulk Pharmaceutical Manufacturers & Products in China.

In early 2006, following a restructure of WiCON’s businesses, James Shen founded Pharma China, now the highly-respected English media and business intelligence service on China's pharmaceutical industry and market which is subscribed by almost all multinational pharmaceutical companies, CROs, consulting companies and investment banking firms active in China.

James Shen was educated in China, Europe and the USA at university and postgraduate levels, and received an MBA from the University of Exeter (UK) in 1990.
He is now based in Beijing with frequent visits to the U.S., Europe and Japan. He continues to be active in strategic consulting with multinational pharmaceutical companies at headquarter and regional head office levels, as well as selective entrepreneurial and VC/PE investment projects in the Chinese healthcare sector.
PREFACE

Despite the enormous business opportunities and growth prospects offered by China’s healthcare sector, I’ve witnessed and experienced countless regulatory and business environmental changes, which has frequently caused painful business difficulties, frustrations and downfalls, in my past 29 years of work in the sector as a consultant, manager and entrepreneur.

The ever-changing legal and market environments in China healthcare present the single biggest challenge to companies and executives operating in the sector. Naturally, many operational level issues and problems in the country also pose significant challenges to successful businesses.

In spite of these challenges and difficulties, the Chinese pharmaceutical industry and market have achieved remarkable growth in the past two decades. The sector is generally developing towards a positive direction in the sense that it continues to grow steadily, its regulatory regime has become increasingly compatible with international standards with improving transparency, once rampant corruption is being tackled, its ongoing consolidation will eventually help establish order and stability, and the country’s new healthcare reform will ultimately led to a more stable and healthier market environment.

There are success stories from all categories of players, whether they are foreign or local, large or small, newcomer or established, private or state-owned. However, to be one of the success stories require a thorough understanding of the sector, ability to face and tackle challenges, flexibility to deal with changes, and skills to maneuver through complex situations.

It has been my wish to put my experience and observations in the past 29 years of operating in almost every aspect of China’s pharmaceutical business into a publication, which will serve as a one-stop reference to anyone seeking to enter or operate in the Chinese pharmaceutical market. As of our 2007 edition, we have been adding a rising number of commentaries and contributions from many other leading pharma industry executives and experts.

Packed with hard-to-find current data and the author’s expert knowledge from years of hard earned experience in the industry, its comprehensiveness, practicality, insight, reliable data and analysis, and up-to-date information, are the features which set this the guide apart from other publications with similar titles.

This Guide is written based on my past experience, interviews with relevant industry experts and government officials, articles from Pharma China, information obtained from or published by Chinese government agencies, information obtained from or published by independent pharmaceutical industry associations, reliable data and released exclusively to WiCON for publication from various reputable market research and consulting firms, information from other trustworthy trade journals and newspapers, related information
found on the internet, and a large in-house information collection by WiCON International Group accumulated since 1991.


The *China Pharmaceutical Guide 2016 (11th Edition)* has been completely reorganized into four volumes:

Volume I – *Overview of the Chinese Pharmaceutical & Healthcare Sectors* (covering update of China’s business environment, history and structure of the Chinese pharmaceutical industry, Chinese health sector structure and statistics, health insurance sector structure and data, as well as disease and drug consumption patterns);

Volume II – *Chinese Pharmaceutical IP and Regulatory Guide* (covering the Chinese drug regulatory system overview, summaries of major healthcare/pharmaceutical related laws and regulations, government agencies and industry associations and pharma IP strategies & legal issues);

Volume III – *Annual Review, Trends, Opportunities and Strategic Considerations* (including a complete review of latest data, business trends, regulatory & IP/legal developments and healthcare reform progress of the Chinese pharmaceutical industry and market in 2015/1H2016, and a large collection of feature articles from industry experts relating to contemporary trends, issues and strategic considerations as well as promising opportunities of the present and future); and

Volume IV – *Sales & Marketing, Entry Strategies and Case Studies* (covering orientation, models and strategies of pharmaceutical sales, marketing and distribution in China, marketing entry strategies and execution, case studies featuring success stories of MNCs and domestic players, R&D and outsourcing, human resource management and legal/IP issues), as well as appendices with full texts of important healthcare/pharmaceutical related policies, laws and regulations.

It is thoroughly updated with ample latest data from many reputable sources, abundant analysis by leading industry experts, new regulations and more case studies. Its coverage was renewed and expanded significantly in the following areas:

- Hundreds of pages of new data, information, analysis and case studies.
- Thorough summaries and analysis of the latest healthcare reform, drug pricing & reimbursement and hospital tender purchase policies.
- Comprehensive industry, market and foreign trade data as well as health statistics are updated with the 2015 (full year) and available figures for the first half of 2016.
- Expanded coverage on e-commerce and digital marketing opportunities, the primary healthcare sector, OTC and consumer healthcare sector, high growth market segments, regional hospital markets, and the pharma distribution sector,
Updated coverage of the Chinese biosimilars/biologics market prospects and regulatory outlook.

Updated coverage of emerging legal issues (including latest Chinese government crackdown on corruption in healthcare, FCPA/compliance and liability issues) and drug-related IP and trademark concerns.

Comprehensive top line data, research findings and observations from our collaborative partners such as IMS Health, Kantar Health, Nicholas Hall, ZS Associates, Rubicon Strategy Group and RDPAC, as well as other reputable sources including the Chinese Pharmaceutical Association, SMEI and Sinohealth.

All regulatory changes in 2015/H12016 are updated to present a clear and most up-to-date picture of the Chinese drug regulatory framework with summaries and analysis of all pharmaceutical related regulations in effect by mid-2015.

Focused coverage of China’s ongoing efforts to revamp its drug regulatory regime through amendments of the Drug Administration Law, its latest proposal and preparations to overhaul the drug pricing mechanism, deepening reform of its drug registration and evaluation regime, new policies to support drug innovation and high clinical value generics, and its initiative to re-evaluate all generic drugs with bioequivalence studies.

An updated section covering proposed new drug-related laws and regulations under drafting process with selective previews of the draft versions.

Extensive review and analysis of China’s drug registration applications and approvals as well as Chinese drug innovation trends in recent years.

Comprehensive review of Sino-foreign M&A, joint venture, strategic alliance, licensing, research partnerships, co-marketing, and new drug research events in 2015 and H1/2016.

Expanded coverage on MNC strategies in China with healthcare reform in the backdrop, intellectual property/patent law amendments, data exclusivity, patent litigation, drug regulations, pharma marketing and distribution strategies, drug consumption patterns, the Chinese R&D and outsourcing sector, clinical studies/practices, healthcare reform, community healthcare sector, essential drug policy, regional drug consumption patterns, and the vaccine and API sectors.

Numerous new case studies are added.

I would like to take the opportunity to thank all those organizations and individuals who contributed to this publication and their continued cooperation is greatly appreciated.

James J. Shen

June 30, 2016
TABLE OF CONTENTS

VOLUME 1 OVERVIEW OF THE CHINESE PHARMACEUTICAL & HEALTHCARE SECTORS .............................................................................................................. 1

ABOUT THE AUTHOR / PUBLISHER ................................................................................................................................. 3

PREFACE .............................................................................................................................................................................. 5

TABLE OF CONTENTS ......................................................................................................................................................... 9

LIST OF TABLES ............................................................................................................................................................... 15

LIST OF CHARTS ............................................................................................................................................................... 29

TABLE OF ABBREVIATIONS ........................................................................................................................................... 31

EXECUTIVE SUMMARY ............................................................................................................................................. 33

PART I OVERVIEW OF THE CHINESE PHARMACEUTICAL SECTOR ............................................................ 37

Chapter I-1 China’s Broad Business Environment ................................................................................................. 39

1.1 Fast Economic Growth and Change ....................................................................................................................... 39
1.2 Integration into the World Economy .................................................................................................................... 40
1.3 Economic Reform .................................................................................................................................................. 41
1.4 WTO Entry Brought Further Reform and Regulatory Changes .......................................................................... 42
1.5 Demographic Trends and Challenges .................................................................................................................. 45
1.6 Rising R&D Investments and Patent Applications ............................................................................................. 49
1.7 Foreign Investment: Structure, Trends & Outlook .................................................................................................. 52
1.8 A Bird’s Eye View of the Contemporary Chinese Economy .................................................................................. 56
1.9 What Will China’s New Normal Look Like? .......................................................................................................... 57
1.10 Foreign Firms Need New Strategies For China’s ‘New Normal’ ....................................................................... 61
1.11 Business Climate and Outlook – Surveys of Foreign Companies in China ......................................................... 63
1.12 Foreign MNCs Fear Unfair Chinese Law Enforcement ....................................................................................... 67

Chapter I-2 Background: The Chinese Pharmaceutical Sector ................................................................................. 70

2.1 Introduction ............................................................................................................................................................. 70
2.2 Government Guidelines for Pharmaceutical Industry Development ............................................................... 76

Chapter I-3 Overview: The Chinese Pharmaceutical Industry .................................................................................. 88

3.1 Overview ............................................................................................................................................................... 88
3.2 The Pharmaceutical Formulation Sector .............................................................................................................. 95
3.3 The Bulk Drug/Active Pharmaceutical Ingredient and Excipient Sector .............................................................. 100
3.4 The Biopharmaceutical Sector ............................................................................................................................. 110
3.5 The Pharmaceutical Distribution Sector .............................................................................................................. 118
3.6 The Human Vaccine Sector .................................................................................................................................... 124
3.7 Pharmaceutical R&D in China – Domestic Chinese Companies ........................................................................ 131
3.8 Pharmaceutical R&D in China – Foreign Companies .......................................................................................... 139
Chapter I-4 Foreign Investment in The Pharma Industry …………………... 174

4.1 China’s Foreign Investment Regulatory Framework ……………………………… 174
4.2 Major Tax Categories for FIEs and Foreigners …………………………………… 188
4.3 Forms of Foreign Investment in the Pharma Sector ……………………………… 191
4.4 Encouraged, Restricted and Banned Areas for Foreign Investment in the Pharma Industry … 191
4.5 Growth of Foreign Investment in the Pharma Sector ………………………… 196
4.6 Contemporary Trends, Issues and Strategic Considerations for Foreign Pharma Investment … 202
4.7 Strategic considerations for MNCs ……………………………………………………… 212

Chapter I-5 The Ethical Pharmaceutical Market ……………………………… 216

5.1 Market Size ………………………………………………………………………….. 216
5.2 Market Prospects and Future Outlook ………………………………………… 218
5.3 Special Characteristics of the Chinese Ethical Pharmaceutical Market ………… 220
5.4 The Hospital Drug Market ………………………………………………………... 221
5.5 The Rise of Retail Pharmacy Sector ………………………………………… 224
5.6 Rural Chinese Market for Ethical Drugs ……………………………………… 232
5.7 Rising Importance of the Primary Healthcare Drug Market ………………… 235
5.8 IMS: Review of Chinese Biologics Market …………………………………… 236

Chapter I-6 The Chinese Vaccine Market ……………………………… 240

6.1 Chinese Vaccine Market Landscape ………………………………………… 240
6.2 Snapshot of Hospital Vaccine Sales in 22 Chinese Cities ……………………… 245
6.3 Market Outlook of the Chinese Human Vaccine Market ………………… 247

Chapter I-7 The OTC Pharmaceutical Market ……………………………… 248

7.1 Overview of the Chinese OTC Market ……………………………………… 248
7.2 Regulatory Progress on OTC Drugs …………………………………………… 251
7.3 China’s OTC and Consumer Healthcare Market Growth to Continue for the Years to Come … 253
7.4 Chinese OTC Drug Market under Rapid Transformation ……………………… 255
7.5 Enthusiastic Pharmaceutical Industry Seeks to Expand OTC Drug Sales …… 256
7.6 Drug Companies Foray into Consumer Healthcare to Counter Pharma Pitfalls … 258
7.7 Healthcare Reform Casts Shadow on Future of the Retail Pharmacy Sector …… 259
7.8 Chinese Online Pharmacy Sales on Sharp Rise Despite Uncertainties Ahead … 260
7.9 CFDA Considers Ban of OTC Drug Ads on Mass Media ………………… 262

Chapter I-8 Pharmaceutical Import and Export ……………………………… 265
PART II  HEALTHCARE PROVISION AND FINANCING .......................... 269

Chapter II-1 Overview ................................................................................. 271
  1.1 Improving Healthcare Provision .......................................................... 271
  1.2 Falling Death Rate and Rising Life Expectancy ...................................... 273
  1.3 Composition of the Chinese Population ............................................... 275
  1.4 Ageing in China: The Implications for Healthcare ................................. 277
  1.5 Economic Burden from Chronic Diseases May Slowdown China’s Growth .... 279
  1.6 2015 Annual Health and Family Planning Sector Development Report .......... 280
  1.7 MOH’s Health China 2020 Strategic Research Report .......................... 284

Chapter II-2 Structure and Composition of Medical Provision .......................... 290
  2.1 Composition of the Chinese Medical Sector ......................................... 290
  2.2 Grade Structure of Chinese Medical Institutions .................................. 293
  2.3 Regional Distribution of Healthcare Resources ...................................... 294
  2.4 Distribution of Healthcare Resources by Medical Specialty ..................... 297
  2.5 Human Resources in China’s Healthcare Industry .................................. 299
  2.6 China Seeks to Establish a General Practitioner System by 2020 ............... 300
  2.7 Government Encourages the Formation of Medical Service Consortiums .. 302
  2.8 Chinese Government Seeks to Boost Private Healthcare ....................... 302
  2.9 China’s Telemedicine Industry Gets Ready To Take Off ....................... 303
  2.10 China’s Mobile Healthcare Sees Sharp Growth .................................... 307
  2.11 Internet Economy to Save China CNY 610B Healthcare Expenditures Annually by 2025 ... 307

Chapter II-3 Healthcare Reform .................................................................. 310
  3.1 A Review of China’s Healthcare System Reform in the Past Three Decades .... 310
  3.2 The Healthcare Reform Plan in the 12th FYP (2011-2015) and 13th FYP (2016-2020) ....... 314
  3.3 Major Healthcare Reform Tasks in 2016 ............................................. 321

Chapter II-4 Healthcare Financing and Insurance Programs ............................ 326
  4.1 Healthcare Financing in China .............................................................. 326
  4.2 Urban Employee Basic Medical Insurance (UEBMI) ................................. 332
  4.3 Urban Resident Basic Medical Insurance Program and New Rural Coop Medical Scheme ... 334
  4.4 Major Medical Insurance Coverage for Urban and Rural Residents ............ 337
  4.5 Work-related Injury Insurance Program .............................................. 337
  4.6 Medical Assistance Program for Civil Servants .................................... 338
  4.7 Maternity Insurance ............................................................................. 339
  4.8 Medical Assistance Program for the Poor ............................................ 340
Chapter II-5 Drug Reimbursement ................................................................. 351
5.1 Drug Reimbursement under BMI, WRI and MI Programs ..................... 351
5.2 A Summary of the MoHRSS Notice for Publication of the 2009 NDRL under BMI, WRI and MI Programs ................................................................. 352
5.3 Common Rules (凡例) of the 2009 NDRL under BMI, WRI and MI Programs .......... 356
5.4 Drug Reimbursement under the New Rural Cooperative Medical System .......... 358
5.5 The Negotiation Mechanism under the 2009 NDRL and NRCMS on Trial .......... 359
5.6 Chinese Government Mulls New Mechanism for NDRL amid Proposed Drug Price Reform 360

Chapter II-6 Measures of Medical Cost-containment .................................. 362
6.1 Price Control .......................................................................................... 363
6.2 Centralized Hospital Drug Purchase Tenders ....................................... 366
6.3 The National Essential Drug System .................................................... 384
6.4 National Formulary and Clinical Guidelines ....................................... 392
6.5 Clinical Pathway/DRGs ........................................................................ 393
6.6 National Drug Price Negotiation ......................................................... 394
6.7 Other Cost-containment Measures ....................................................... 396
6.8 Tiered Medical Service System ............................................................ 398

PART III  DISEASE AND DRUG CONSUMPTION PATTERNS .................. 401

Chapter III-1 Growth of Drug Consumption and Demand .................. 403
1.1 Sharp Growth in Drug Consumption and Healthcare Expenditures .......... 403
1.2 The State of Health of the Chinese Population .................................... 407
1.3 Health Awareness and Literacy ............................................................. 408
1.4 Aging Population and Increased Demand on Healthcare In China .......... 408
1.5 Medical and Public Health Services ..................................................... 411

Chapter III-2 Popular Diseases and Morbidity ........................................ 413
2.1 Leading Diseases in Recent Years ......................................................... 413
2.2 Leading Causes of Death .................................................................... 417
2.3 An Extensive Overview of Chronic and Epidemic Diseases in China .......... 420
2.4 Recent Chinese Therapeutic Trends in Diabetes, Hepatitis B and Oncology .... 437
2.5 Prevalent Health Problems to Senior Citizens in China ....................... 452
2.6 Chinese in Good Health Longer Than People in Other G20 Countries .......... 454

Chapter III-3 Medical institution Attendance and Expenses ...................... 456
3.1 Composition of Medical Care System in China .................................... 456
3.2 Hospital Attendance ............................................................................ 457
3.3 Healthcare Expenditures and Medical Expenses ................................. 462

Chapter III-4 Drug Consumption Patterns in Medical institutions .............. 470
Chapter III-5 Retail Drug Consumption Patterns ........................................537
  5.1 Review of the Chinese Retail Pharmacy Market .............................537
  5.2 Consumption Patterns of Retail Pharmacy Sales of Medicine and Health Products ............................539
  5.3 Structure of Chinese B2C Online Pharmacy Market .......................557

Chapter III-6 Consumption Patterns of OTC Drugs ..................................562
  6.1 Structure of Chinese OTC Drug Sales ......................................562
  6.2 Leading Chinese OTC Companies and Brands .............................565
  6.3 How to Succeed in China’s Challenging OTC Environment ...............569
  6.4 China OTC Market Has Growth Potential despite Regulatory Uncertainty .........................572

Chapter III-7 Consumption Patterns of Formulated Traditional Chinese Medicines ...577
  7.1 IMS Data ...................................................................................577
  7.2 SMEI Data ..............................................................................581
  7.3 Sinohealth Data ........................................................................588

Chapter III-8 Regional Drug Consumption Patterns ..................................589
  8.1 Gap Between Cities and Rural Areas .........................................589
  8.2 Regional Hospital Markets for Drug Products ..............................590
  8.3 Regional Markets by Pharmaceutical Distributor Sales ..................596
  8.4 Regional Retail Pharmacy Markets for Drug Products ..................598
  8.5 Regional OTC Drug Markets .....................................................601
  8.6 Regional Primary Healthcare Drug Markets ................................603

Chapter III-9 Market Shares of Local, JV and Imported Drugs ....................607
  9.1 Hospital Market – Local vs. JV vs. Imported Drugs .......................607
  9.2 Retail Pharmacy/OTC Market – Domestic Companies vs. JV/Foreign Players ....................615
  9.3 Future Trends and Outlook .......................................................616

VOLUME 2 CHINESE PHARMACEUTICAL IP AND REGULATORY GUIDE .................................................................621

TABLE OF CONTENTS ...........................................................................623
LIST OF TABLES ..................................................................................627
LIST OF CHARTS ................................................................................629
TABLE OF ABBREVIATIONS ........................................................................................................... 631

PART IV CHINESE PHARMACEUTICAL REGULATORY AND IP GUIDE .................................................................................. 633

Chapter IV-1 Overview .................................................................................................................. 635

1.1 Drug Regulation Statistics ........................................................................................................ 635
1.2 Overview of Drug Evaluation and Registration ...................................................................... 637
1.3 Adverse Drug Reaction and Drug Abuse Reporting ............................................................... 644
1.5 Major Drug-related Policies, Regulations and Laws under Drafting Process ......................... 649
1.6 Drug Regulatory Direction in 2015 ......................................................................................... 653
1.7 Reform of China’s Drug Evaluation and Approval System ..................................................... 654
1.8 CFDA’s Plan to Phase in Bioequivalence Study on Generic Drugs ........................................ 662

Chapter IV-2 Important Laws and Regulations ........................................................................... 665

2.1 The Drug Administration Law of the People’s Republic of China ........................................ 665
2.2 Regulations for Implementation of the Drug Administration Law of the PRC .................... 668
2.3 Major Regulations under the Drug Administration Law of PRC (2001) .............................. 673
2.4 Other Drug Related Laws and Regulations ......................................................................... 675

Chapter IV-3 Major Government Agencies and Industry Associations in Pharma ..................... 678

3.1 The China Food and Drug Administration (CFDA) .............................................................. 679
3.2 The Center for Drug Evaluation under the CFDA ................................................................. 688
3.3 National Development and Reform Commission (NDRC) ..................................................... 690
3.4 The National Health and Family Planning Commission (NHFPC) ...................................... 694
3.5 Ministry of Human Resources and Social Security (MOHRSS) ............................................ 702
3.6 Ministry of Industry and Information Technology (MIIT) ..................................................... 703
3.7 Ministry of Commerce (MOFCOM or MOC) ......................................................................... 704
3.8 State-owned Assets Supervision and Administration Commission of the State Council .... 704
3.9 State Administration of Traditional Chinese Medicine (SATCM) ........................................ 705
3.10 Pharmaceutical Industry Associations in China ................................................................. 706

Chapter IV-4 Drug Regulatory Framework in China (1) - Drug Registration Regime ............... 711

4.1 Overview ............................................................................................................................... 711
4.2 General principles of Provisions for Registration of Drug Products .................................... 713
4.3 Clinical Research for Drug Registration ............................................................................... 716
4.4 Rules and Technical Guidelines for Drug Research ............................................................. 717
4.5 Multi-Regional Clinical Trials (MRCT) ................................................................................ 719
4.6 Acceptance of Foreign Preclinical Study Data ..................................................................... 721
4.7 Rules for Special Approval of Drug Registration ................................................................. 721
4.8 New Drug Surveillance Period ............................................................................................ 723
4.9 Registration of Copy/Generic Drug and Their Quality/Efficacy Equivalence Studies .......... 724
4.10 Registration of Import Drugs ............................................................................................. 732
4.11 Re-Registration of Imported Drugs ........................................... 736
4.12 Registration of Biosimilars ......................................................... 737
4.13 Registration of OTC Drugs ............................................................ 738
4.14 Registration of Certain Drug Related Products .................................... 738
4.15 Supplemental Requirements for Registration of Traditional Chinese Medicines .......................... 740
4.16 Applications and Approvals for Supplemental Registrations ....................... 740
4.17 Drug Registration Reconsideration .................................................. 741
4.18 Post Approval Changes to Pharmaceuticals ......................................... 743
4.19 Onsite Verification for Drug Registration ......................................... 744
4.20 The Drug Evaluation Regime ........................................................ 744
4.21 Chinese Pharmacopoeia (ChP) .................................................... 745
4.22 GLP/Preclinical Research and GCP/Clinical Research .......................... 746
4.23 China Piloting Drug Marketing Authorization Holder (MAH) System ............... 752

Chapter IV-5 Drug Regulatory Framework in China (2) – Others .......................756
5.1 Pharmaceutical Manufacturer Licensing ........................................... 756
5.2 Contract Manufacture/OEM ............................................................ 758
5.3 Pharmaceutical Manufacturing and GMP Certification ........................ 764
5.4 Regulation of Pharmaceutical Excipients .......................................... 768
5.5 Drug Labeling and Packaging ........................................................ 771
5.6 Pharmaceutical Distribution Licensing .............................................. 776
5.7 Pharmaceutical and Vaccine Distribution/GSP ..................................... 780
5.8 Drug Import Process ....................................................................... 787
5.9 Pharmaceutical Regulatory Inspections and Enforcements ....................... 790
5.10 Classified Control of Drug Products ............................................... 791
5.11 Drug Advertising .......................................................................... 795
5.12 Drug Pricing and Price Control ....................................................... 803
5.13 Post-marketing Surveillance/ADR Reporting ...................................... 809
5.14 Counterfeit, Fake and Sub-standard Drugs ......................................... 817
5.15 Control of Narcotics and Psychotropic Drugs ................................... 823
5.16 Internet Information Service and Online Sales of Drug Products ................. 827
5.17 Drug Prescription/Rational Drug Use/Clinical Practices ........................ 831
5.18 Pharmaceutical Technology Transfer / Administrative Protection / IP ........... 842
5.19 Anti-corruption/Compliance/Black Listing/Drug Donation ...................... 846
5.20 Drug Donations ............................................................................. 852
5.21 International Regulatory Cooperation ............................................... 857
5.22 Others ............................................................................................ 864

Chapter IV-6 Intellectual Property Rights and Legal Issues .............................867
6.1 Pharmaceutical Patent Protection ..................................................... 871
6.2 Administrative Protection of Pharmaceuticals (APP) ............................ 893
6.3 Data Exclusivity ............................................................................. 899
6.4 Patent and Trademark Registration .................................................... 901
Chapter VI

6.5 Patent and IP Strategies for China .......................................................... 909
6.6 Protecting and Policing IPRs in China ...................................................... 911
6.7 Administrative Enforcement of Patents in China ....................................... 913
6.8 Pharmaceutical Patent Litigation in China ............................................... 916
6.9 Trade Secret Protection ........................................................................... 921
6.10 Counterfeit Drugs .................................................................................. 923
6.11 Judicial Interpretations of Law Applications over Drug Safety ................ 926
6.12 The Tort Liability Law: Impacts on Pharma ........................................... 933
6.13 Compliance and Corruption Risks .......................................................... 937
6.14 Antitrust/Antimonopoly ......................................................................... 948
6.15 Merger & Acquisitions .......................................................................... 961

VOLUME 3 ANNUAL REVIEW, TRENDS, OPPORTUNITIES & STRATEGIC CONSIDERATIONS ................................................................. 973

TABLE OF CONTENTS .................................................................................. 975
LIST OF TABLES ............................................................................................ 979
LIST OF CHARTS ........................................................................................... 982
TABLE OF ABBREVIATIONS ....................................................................... 983

PART V ANNUAL REVIEW AND OUTLOOK OF THE CHINESE PHARMACEUTICAL INDUSTRY AND MARKET ................................................. 985

Chapter V-1  The Broad Chinese Economy: Review and Outlook ................... 987

Chapter V-2  Annual Review of the Chinese Pharmaceutical Industry and Market ... 990
2.1 Current Overview of the Chinese Pharmaceutical Market ....................... 990
2.2 Overview of Pharmaceutical Industry Performance ................................ 999
2.3 Annual Review of Regulatory Developments ......................................... 1010
2.4 Healthcare Reform Stumbles on amid a Matrix of Government Policies ...... 1026
2.5 Pharma Industry Needs to Recalibrate and Reposition for New Business Environment ...... 1040
2.6 Old IP Issues Remained As China Steps Up Antimonopoly Enforcements ...... 1052

Chapter V-3  Review of Chinese Pharma M&A, Licensing and Collaborative R&D Deals in 2015 and 1H2016 ................................................................. 1056

Chapter V-4  What Does the Future Hold for China's Healthcare Economy? ....... 1073
4.1 China Comes Down from the Altar of Economic Miracle ....................... 1073
4.2 Challenges Abound in the Near Term As Longer Term Outlook Improves ...... 1074
4.3 13FYP Paints a Gloomy Picture for Healthcare MNCs ............................ 1087
4.4 Healthy Future Predicted for China Healthcare and Pharmaceuticals .......... 1089

PART VI CONTEMPORARY TRENDS, OPPORTUNITIES AND STRATEGIC CONSIDERATIONS ................................................................. 1093

Chapter VI-1  Introduction .......................................................................... 1095
**Chapter VI-2  Market Dynamics and Strategic Considerations**

<table>
<thead>
<tr>
<th>2.1</th>
<th>Impacts of Slowing Chinese Economy on the Country’s Healthcare Plans</th>
<th>1097</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.2</td>
<td>Healthcare Reform in China May Be A Double-Edged Sword For Foreign Companies</td>
<td>1099</td>
</tr>
<tr>
<td>2.3</td>
<td>What Should We Know about the Merger of China’s Urban and Rural Resident Basic Medical Insurance Schemes?</td>
<td>1101</td>
</tr>
<tr>
<td>2.4</td>
<td>Embracing China’s Brave New Pharmaceutical World</td>
<td>1103</td>
</tr>
<tr>
<td>2.5</td>
<td>Chinese Pharma: A Global Health Game Changer?</td>
<td>1107</td>
</tr>
<tr>
<td>2.6</td>
<td>An Unexpected Reality in the Post-GSK World</td>
<td>1110</td>
</tr>
<tr>
<td>2.7</td>
<td>What Happens When MNCs Need The China Market More Than China Needs FDI?</td>
<td>1112</td>
</tr>
<tr>
<td>2.8</td>
<td>Big Pharma Emerging Market Tactics Shift as Growth Slows</td>
<td>1114</td>
</tr>
<tr>
<td>2.9</td>
<td>RDPAC and PhRMA Advocates for Innovation-driven Pharma Industry in China</td>
<td>1115</td>
</tr>
<tr>
<td>2.10</td>
<td>A Lost Generation of New Products</td>
<td>1117</td>
</tr>
<tr>
<td>2.11</td>
<td>Cross-Sector Collaboration to Enhance Market Access for Pharmaceutical Companies in Asia: Six Steps to Make It Work</td>
<td>1119</td>
</tr>
<tr>
<td>2.12</td>
<td>Will Apple’s Business Model Work in Pharmaceuticals?</td>
<td>1123</td>
</tr>
<tr>
<td>2.13</td>
<td>Are These the Meaningful Changes at the CFDA We’ve Been Waiting For?</td>
<td>1126</td>
</tr>
<tr>
<td>2.14</td>
<td>Low Chinese Household Income a Challenge for MNCs</td>
<td>1128</td>
</tr>
<tr>
<td>2.15</td>
<td>Big Pharma Facing Roadblock in China</td>
<td>1129</td>
</tr>
<tr>
<td>2.16</td>
<td>Are You Ready for the Lower Tier Market?</td>
<td>1131</td>
</tr>
<tr>
<td>2.17</td>
<td>China’s Policy Environment – Local, Local, Local</td>
<td>1132</td>
</tr>
<tr>
<td>2.18</td>
<td>Leading Chinese Pharma Companies Eyes The Medical Service Sector</td>
<td>1133</td>
</tr>
<tr>
<td>2.19</td>
<td>How is the Reputation of Chinese Pharmaceutical Industry?</td>
<td>1135</td>
</tr>
<tr>
<td>2.20</td>
<td>Review of Off-label Drug Usage in Chinese Hospitals</td>
<td>1137</td>
</tr>
<tr>
<td>2.21</td>
<td>Physician-Patient Relations and Health Literacy in China</td>
<td>1138</td>
</tr>
<tr>
<td>2.22</td>
<td>China Healthcare Advertising: Failure to Learn</td>
<td>1141</td>
</tr>
<tr>
<td>2.23</td>
<td>Growing Problem of Counterfeit Drugs</td>
<td>1142</td>
</tr>
<tr>
<td>2.24</td>
<td>What Is Venture Capital Up to in China’s Life Science Space?</td>
<td>1143</td>
</tr>
<tr>
<td>2.25</td>
<td>Regulatory Changes in China to Impact Development &amp; Manufacturing Strategies</td>
<td>1145</td>
</tr>
<tr>
<td>2.26</td>
<td>How Patient Do Chinese Patients Need To Be for Innovative New Drugs?</td>
<td>1147</td>
</tr>
<tr>
<td>2.27</td>
<td>China’s Life Science Innovative Development Policies</td>
<td>1150</td>
</tr>
<tr>
<td>2.28</td>
<td>Strategic Domains in The U.S.-China Life Science Sector</td>
<td>1152</td>
</tr>
<tr>
<td>2.29</td>
<td>Pharma MNCs are on the Defensive. Are They Thinking Clearly?</td>
<td>1153</td>
</tr>
</tbody>
</table>

**Chapter VI-3  Promising Opportunities of the Present and Future**

<table>
<thead>
<tr>
<th>3.1</th>
<th>Chinese Healthcare Expenditures to Triple by 2020 Despite Challenges</th>
<th>1156</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.2</td>
<td>Commercial Models in China’s Pharma Sector Must Change</td>
<td>1159</td>
</tr>
<tr>
<td>3.3</td>
<td>Time to Rethink about Your OTC/Consumer Healthcare Strategies in China</td>
<td>1160</td>
</tr>
<tr>
<td>3.4</td>
<td>Tapping China’s Burgeoning Biosimilar Market</td>
<td>1162</td>
</tr>
<tr>
<td>3.5</td>
<td>Two Way Traffic for Chinese Drug Licensing</td>
<td>1168</td>
</tr>
<tr>
<td>3.6</td>
<td>Chinese Market Offers New Life to Many Drugs</td>
<td>1170</td>
</tr>
<tr>
<td>3.7</td>
<td>MNCs Boost Drug Research and Clinical Trials for Diseases Prevalent in China and Other Asian Markets</td>
<td>1172</td>
</tr>
</tbody>
</table>
Chapter VI - 4  Trends and Prospects in Pharma Outsourcing

4.1  CMO/Manufacturing Outsourcing in China and Asia ........................................ 1225
4.2  Will China Lose Its Cost-Competitiveness in Pharma Manufacturing? .................. 1234
4.3  Chinese CRO Market Estimated to Grow 20% Annually Before 2018 ..................... 1237
4.4  Trends and Prospects of Clinical Research in China ........................................... 1238
4.5  SCPRR Survey Expects Growing Clinical Trials in China .................................... 1243
4.6  Potential Compliance Risks in Clinical Research Outsourcing to China .................. 1244
4.7  The Next Hotspots for CMO/CRO Growth in China ........................................... 1248
### Chapter VII-2 Major Promotional Practices and Government Affairs 1279

2.1 National and Local Drug Reimbursement Lists .......................... 1279
2.2 Pricing of Drug Products .................................................................... 1281
2.3 Centralized Hospital Drug Purchase Tenders .................................... 1282
2.4 Product Launches ............................................................................. 1284
2.5 Clinical Research .............................................................................. 1285
2.6 Public Relations .................................................................................. 1286
2.7 Lobbying for Industrial Policies and Regulations ............................... 1286
2.8 Investing in Government Affairs to Access Your Market Potential in China: Key Considerations 1287
2.9 Only 12.1% of the Doctors Are Satisfied with the Domestic Academic Meetings .......... 1292
2.10 Measuring Pharma’s Success by Customer Reputation and Loyalty ...................... 1298

### Chapter VII-3 Marketing and Sales of Ethical Drugs in Urban Hospitals 1303

3.1 Mainstream Hospital Marketing and Sales Models ............................ 1303
3.2 The Hospital Drug Purchase Approval Process .................................. 1304
3.3 Hospital Drug Purchase Channels ...................................................... 1306
3.4 Hospital Marketing/Sales Organization and Execution ....................... 1307
3.5 Key Factors in Hospital Marketing and Sales ...................................... 1308
3.6 Developing Effective Market Coverage and Sales Force Strategies in China .......... 1309
3.7 Shifting from Network Marketing to Evidence Based Medicine in China .................. 1312
3.8 More Chinese Pharma Cos Cuts Sales Force and Switch to Agency Sales .............. 1314

### Chapter VII-4 Marketing and Sales of Ethical Drugs through Urban Retail Pharmacies 1316

4.1 Channels of Retail Pharmacy Sales and Distribution ........................ 1316
4.2 Process and Key Components of Retail Pharmacy Sales ..................... 1317
4.3 Key Factors in Sales of Ethical Drugs through Retail Pharmacies ............ 1317
4.4 Case in Point: Pfizer’s Retail Pharmacy Sales Efforts in China .................. 1318

### Chapter VII-5 Sales & Marketing of OTC Drug Products in Cities 1320

5.1 Channels of OTC Drug Sales .............................................................. 1320
5.2 Process and Key Components of OTC Drug Sales ............................. 1321
5.3 Key Factors in OTC Drug Sales .......................................................... 1322

### Chapter VII-6 Sales, Marketing and Distribution of Drugs in the "Third Terminal Market" 1324

6.1 Pharmaceutical Sales & Distribution Channels to the "Third Terminal Market" .......... 1324
6.2 Sales and Marketing Strategies for the "Third Terminal Market" .................... 1325
PART VIII  MARKET ENTRY STRATEGIES AND EXECUTION .............. 1379

Chapter VIII-1 Preparations for a Market Entry Strategy .................. 1381
  1.1 The Need for a Market Entry Strategy ....................................... 1381
  1.2 Long Term Perspective ................................................................... 1381
  1.3 Information Sources ......................................................................... 1382
  1.4 Getting Expert Help ......................................................................... 1385
  1.5 Market Research ............................................................................... 1385
  1.6 Selecting the Right Products ............................................................... 1386
  1.7 China’s Evolving Pharma Partnering Landscape: The Right Partner Profile .......................................................... 1387

Chapter VIII-2  Strategic Approaches for Market Entry .......................... 1392
PART IX  MINI CASE STUDIES................................. 1447

Chapter IX-1  China Experiences of Foreign Drug Companies ................. 1449

1.1 Quest PharmaTech's Ill-fated China Venture ........................................... 1449
1.2 Ranbaxy's Successful Entry and Surprising Exit of the Chinese Market .... 1450
1.3 Zuellig Pharma China/Cardinal Health China – A Successful Case and Business Model for China's Pharmaceutical Distribution Sector .................................................. 1453
1.4 West Pharmaceutical Services - Tapping into China's Growing Healthcare Industry .............................................................. 1456
1.5 Novo Nordisk China - Focusing on Diabetes ........................................... 1458
Chapter IX -  R&D and Outsourcing Case Studies ................................. 1500

2.1  Birth of A New Novel Anticancer, Made in China .............................. 1500
2.2  Chine Becomes Center of Startup CROs for Basic Research .................. 1501
2.3  Huya Bioscience - Tapping into China for Novel Drug Candidates .......... 1507
2.4  LEAD Therapeutics: A Unique US-China Drug Discovery Model .......... 1508
2.5  BeiGene Strives to Become China’s Genentech .................................. 1510
2.6  Two Emerging Companies Leverage the Strength of Both China and the U.S. for Growth 1512
2.7  Chinese Innovation: BGI’s Code for Success ..................................... 1515
2.8  Human Genomics in China: 10-Year Endeavor ................................... 1519
2.9  China Learns the Lesson of Vaccine R&D Bubble - The Story of Chongqing Brewery’s in Development of Its Novel HepB Vaccine .............................................. 1525
2.10 Research Partnership between BMS and Simcere: The Right Chemistry amid a Global Paradigm Shift of Drug R&D ................................................................. 1527
2.11  China’s Academic “Black Market” Fooled Canadian Medical Journal .......... 1532
2.12  A Setback For Chinese Drug R&D ....................................................... 1534
2.13  USFDA Found China Data Irregularities for Key Study of Pfizer and BMS’s Eliquis .......... 1538
2.14  How Chinese Suppliers to Global Drug Firms Hide Bad Test Results .......... 1539
2.15  TCM Gets a Modern Look ................................................................. 1541
2.16  Chinese Companies Make Progress on New Drugs from TCM Herbs .......... 1543
2.17  Novartis CEO on Why the Firm Just Opened a Major R&D Facility in China ............ 1545
Chapter IX-3  Human Resource Management Case Studies .................................1548
  3.1 AstraZeneca China: Continued Mission on People ...............................................1548
  3.2 Novartis China: The Learning Strategy ...............................................................1549
  3.3 Trends in Managing Pharmaceutical R&D and Medical Affairs Professionals ........1551

Chapter IX-4  Legal Case Studies: IPR/Counterfeits/AML/Others .........................1556
  4.1 Sankyo vs. Beijing Wansheng: First Lawsuit over Process Patent for Preparing Pharmaceutical Composites .................................................................1556
  4.2 Pfizer vs. 12 Local Drug Companies: Landmark Lawsuit over Viagra Patent ..........1557
  4.3 Eli Lilly vs. Beijing Ganli - Battle over Insulin ....................................................1559
  4.4 Boehringer Ingelheim vs. Chaitai Tianqing over Tiotropium Bromide ..................1560
  4.5 Legal Battle between Sanofi and Jiangsu Hengrui over Docetaxel .........................1561
  4.6 Merck vs. Henan Topfond over Chinese Patent for Finasteride ..........................1562
  4.7 Aurisco Challenges Gilead’s Chinese Patent for Viread .....................................1563
  4.8 Fake Drug Sting Operation – GSK Experience .....................................................1564
  4.9 Legal and Ethical Implications of ELAD Clinical Trial Death ...............................1565
  4.10 Ruling over Liabilities of Distributors and Hospital in Fake Armillarisni-A Inj. Case ...1567
  4.11 Novartis Sued and Challenged for Deaths Linked to Its Hepatitis B Drug Sebivo ....1568
  4.12 Illegal and Off-Label Use of Roche’s Avastin Led to Serious ADRs in Shanghai ......1570
  4.13 Off-label Use of Bayer Healthcare’s XARELTO under Challenge in China ..........1571
  4.14 Review of the 11-Year Trademark Fight between Roche and Southwest Pharma ...1573
  4.15 Merck & Co. Loses Trademark Fight against Tianjin Zhongxin Pharma .................1576
  4.16 Pfizer Loses Final Battle for Chinese Trademark of Viagra ................................1576
  4.17 Johnson & Johnson Loses Trademark Lawsuit against SAIC’s Trademark Review Board,..1577
  4.18 Bayer Settles Six-Year Trademark Infringement Lawsuit with Henan Baier Pharma ...1577
  4.19 The Rio Tinto Case Lays New Ground for PR of Foreign Companies in China .........1578
  4.20 Siemens Sued in the U.S. by Former Employee over Briberies in China ...............1581
  4.21 China’s Anti-Japanese Boycott Extended to Pharmaceuticals ...............................1582
  4.22 The Impact of Restricted Data-flows on China’s Digital Healthcare Solutions .........1584
  4.23 Insight Into PRB Decisions on Pharma/Biotech Inventions Around 2015 ..............1586
  4.24 SIPO Invalidates Gilead Sciences’ Viread Patent in China ................................1589
  4.25 China Rejects Patent for Gilead’s Expensive Hepatitis C Drug ..........................1590
  4.26 Bayer Loses Avelox (Moxifloxacin) Patent Battle in China ................................1592
  4.27 Eli Lilly vs. Changzhou Watson: China’s Supreme Court Sides with Local Firm After Court Designated Technical Investigations .........................................................1592
  4.28 Review of China’s High Profile Investigation of GSK for Corruption .................1593
  4.29 The “Dignified” Drug-Dealer – A Case for Thought over Patient Access to Medicines, Parallel Import, Compulsory Licensing and Drug Pricing ..................................1608
  4.30 Anti-Monopoly Enforcement Cases .................................................................1611
  4.31 Pfizer Fined by Shanghai Government for Irregular Pharmacy Display Fees ...........1615

Chapter IX-5  Case Study: Success Stories of Domestic Companies .......................1617
5.1  BGI: The Kung Fu Panda of the Genomic World ........................................................................ 1617
5.2  China’s Bid To Be A DNA Superpower ................................................................................ 1620
5.3  3SBio – The Success Story of a Chinese Biogeneric Company .............................................. 1623
5.4  Shanghai Sunway Biotech Co. Ltd. – The Success Story of a Chinese Gene Therapy Drug Company ........................................................................................................... 1626
5.5  SinoVac Biotech – The Story of a Chinese Vaccine Developer .............................................. 1628
5.6  Zhejiang Hisun Pharmaceutical Ltd. – A Showcase for International Business Transformation of Chinese Pharma Companies .................................................................................. 1630
5.7  Jiangsu Hengrui Pharmaceutical – What Does the Future Hold for China’s Largest Oncology Drug Firm? ................................................................................................................ 1635
5.8  Tongji tang Chinese Medicines Company – The Tale of a Fallen Wall Street Darling and One of the Earliest “China Concept” Drug Stocks ........................................................................ 1637
5.9  Shenogen Pharma Blends East and West ................................................................................. 1640
5.10 GenePharma - The Story of a Small Niche Chinese Biotech Company ................................. 1643
5.11 Luqa Pharmaceuticals – Expatriate-founded Chinese Pharma Startup with a Strategy of Tailoring Products for China through Partnerships ..................................................... 1645
5.12 The Rise and Fall of Simcere Pharmaceutical as a US-listed Company ............................... 1647
5.13 Fosun Pharma Expands Global Business Via M&As and Innovative R&D ........................... 1648

APPENDICES .............................................................................................................................. 1651

Appendix I  Drug Administration Law of the PRC ................................................................. 1653
Appendix II  Regulations for Implementation of the Drug Administration Law of PRC ................................................................................................................................. 1672
Appendix III  Regulations on Administrative Protection for Pharmaceuticals ............. 1690
Appendix IV  Provisions for Drug Registration ................................................................. 1694
Appendix V  Special Review and Approval Procedure for Drug Registration of CFDA ........................................................................................................... 1725
Appendix VI  Administrative Reconsideration Measures of CFDA ........................................ 1731
Appendix VII  Provisions for Drug Insert Sheets and Labels ............................................ 1737
Appendix VIII  Provisions for Supervision of Drug Distribution ..................................... 1742
Appendix IX  Provisions for Drug Advertisement Examination ....................................... 1748
Appendix X  The Official Healthcare Reform Plan .............................................................. 1755
LIST OF TABLES

Table 1.1 Number of Pharmaceutical Businesses in China Since 1997 ......................... 88
Table 1.2 Chinese Pharma Industry by Sales in 2005-2015 ........................................... 90
Table 1.3 Sales Revenues Value and Profits of Listed Pharma Cos in 2006-2015........ 91
Table 1.4 Growth of the Chinese API/Bulk Drug Sector 2002-2015 .......................... 100
Table 1.5 China-based Pharma Companies with U.S. DMFs ........................................ 102
Table 1.6 Summary of U.S. DMFs Filed Products Manufactured in China ............... 103
Table 1.7 Top 15 China-based DMF Holders with Ten or More Active DMFs .......... 103
Table 1.8 Chinese Foreign Trade of Biochemical Drugs 2007-2015 (US$ mln).......... 113
Table 1.9 Biologic Registration Applications Accepted by the CDE in 2012-2015 .... 114
Table 1.10 Breakdown of CDE Recommendations for Biologic Applications in 2015 114
Table 1.11 # of Concluded Biologic Registration Applications by CDE 2012-2015 ... 114
Table 1.12 Important Drug/Biologic Approvals in 2015 .................................................. 115
Table 1.13 Number of Pharma Distribution License Holders 2013-2015 ................. 118
Table 1.14 Structure of Chinese Retail Pharmacy Sector 2006-2015 ......................... 118
Table 1.15 Top 20 Chinese Pharma Wholesale Distributors by Capacity in 2013 ...... 119
Table 1.16 R&D Centers of RDPAC Members in China .................................................. 141
Table 1.17 Outbound Sino-Foreign Licensing Deals in 2015 and Early 2016 .......... 152
Table 1.18 Number of Pharma Industry M&A in China 2011-3Qs/2015 ..................... 160
Table 1.19 Top 8 Oversea M&A Deals by Chinese Pharma/Healthcare Companies..... 161
Table 1.20 Revenue Distribution of the Top 100 Chinese Pharma Cos 2005-2015 ...... 163
Table 1.21 Revenue Size of the 100th Chinese Pharma Company in 2005-2015 ........ 163
Table 1.22 Share of Top 100 in Total Chinese Pharma Industry Sales 2005-2015 ....... 164
Table 1.23 Regional Distribution of Top 100 Pharma Cos by Sales 2005-2015 ......... 164
Table 1.24 Subsectors of Top 100 Chinese Pharma Cos by in 2005-2015 ............. 164
Table 1.25 Publicly-listed Firms in Top 100 Chinese Pharma Cos by Sales 2009-2015 165
Table 1.26 Top 20 Chinese Pharma-Chem Cos by Overall Competitiveness in 2015 .. 165
Table 1.27 Top 20 Domestically Listed Chinese Pharma Companies H1/2016 ......... 166
Table 1.28 Top Ten Listed Chinese Pharma Companies by Capitalization in 2015 ..166
Table 1.29 Profit Margin of Chinese API Subsector 2010-2015..........................167
Table 1.30 Top 10 Listed API Companies by Net Profit 2015............................167
Table 1.31 Profit Margin of Chinese Pharma Formulation Subsector 2010-2015......167
Table 1.32 Top 10 Listed Pharma Formulation Companies by Net Profit 2015......168
Table 1.33 Profit Margin of Chinese Biologics Subsector 2010-2015..................168
Table 1.34 Top 10 Listed Biologics Companies by Net Profit 2015......................168
Table 1.35 Top 20 Listed Pharma Companies by R&D Investment 2012-2014.......169
Table 1.36 Top 20 Chinese Distributors by Sales Revenues in 2015....................170
Table 1.37 Top 20 Chinese Retail Pharmacy Chains by Sales Revenues in 2015.....171
Table 1.38 Top 20 Chinese Retail Pharmacy Chains by 2015 Sales.....................172
Table 1.39 Encouraged Areas under the 2015 Foreign Investment Industrial Guidance Catalogue (Healthcare and Life Science)..................................................194
Table 1.40 Restricted Areas under the 2015 Foreign Investment Industrial Guidance Catalogue (Healthcare and Life Science)..................................................194
Table 1.41 New Foreign Investment in Chinese Pharma Industry 2013...............197
Table 1.42 First Ten Sino-Foreign Pharmaceutical Joint Ventures in China.........197
Table 1.43 Foreign Investment in the Chinese Pharmaceutical Industry in the 1990s ..198
Table 1.44 Pharma Foreign Investments in China between 2000 and 2006 ............198
Table 1.45 Top 10 Pharma MNCs in China by Investment..............................200
Table 1.46 Chinese Prescription Drug Market Segmentation 2013-2015..............216
Table 1.47 Chinese Biologics Market Structure by TCs 2014..........................237
Table 1.48 Chinese Biologics Market Structure by Chemical Identities 2014 ......237
Table 1.49 Urban Biologics Market Structure by Disease Areas 2014..................238
Table 1.50 Top 10 Biologics Companies in China 2014..................................238
Table 1.51 Top 10 Domestic Biologics Companies in China 2014......................239
Table 1.52 Chinese Vaccine Market 2006-2014...........................................242
Table 1.53 Vaccine Consumption at Rep Chinese Hospitals 2010-2015.............245
Table 1.54 Chinese Vaccine Market Structure 2014 ......................................246
<table>
<thead>
<tr>
<th>Table 1.55 Chinese Hep B Vaccine Market Shares of Producers H1/2015</th>
<th>246</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 1.56 Chinese Hep A Vaccine Market Shares of Producers H1/2015</td>
<td>246</td>
</tr>
<tr>
<td>Table 1.57 Chinese PPV 23 Market Shares of Producers H1/2015</td>
<td>246</td>
</tr>
<tr>
<td>Table 1.58 Chinese OTC Drug Market Overview 2014-2015 (%)</td>
<td>248</td>
</tr>
<tr>
<td>Table 1.59 Chinese OTC Drug Market Growth Rates 2011-2015 (%)</td>
<td>249</td>
</tr>
<tr>
<td>Table 1.60 Chinese OTC Drug Market 2012-2015</td>
<td>249</td>
</tr>
<tr>
<td>Table 1.61 Structure of Chinese OTC Drug Market 2015</td>
<td>249</td>
</tr>
<tr>
<td>Table 1.62 Growth of OTC Drug Market Segments in 2013-2015</td>
<td>250</td>
</tr>
<tr>
<td>Table 1.63 Chinese Retail Pharmacy Market Growth Drivers 2015</td>
<td>250</td>
</tr>
<tr>
<td>Table 1.64 Chinese OTC Drug Market Segmentation 2013-2015</td>
<td>251</td>
</tr>
<tr>
<td>Table 1.65 Number of Approved Chinese Online Pharmacies</td>
<td>260</td>
</tr>
<tr>
<td>Table 2.1 Improvement of Medical Provision in China</td>
<td>271</td>
</tr>
<tr>
<td>Table 2.2 Comparisons of Healthcare Provision by China vs. Other Countries (1)</td>
<td>272</td>
</tr>
<tr>
<td>Table 2.3 Comparisons of Healthcare Provision by China vs. Other Countries (2)</td>
<td>272</td>
</tr>
<tr>
<td>Table 2.4 Birth, Death and Population Natural Growth Rate</td>
<td>273</td>
</tr>
<tr>
<td>Table 2.5 Rising Life Expectancy of the Chinese Population</td>
<td>274</td>
</tr>
<tr>
<td>Table 2.6 Composition of the Chinese Population by Urban/Rural Division and Sex</td>
<td>275</td>
</tr>
<tr>
<td>Table 2.7 Composition of the Chinese Population by Age</td>
<td>276</td>
</tr>
<tr>
<td>Table 2.8 Composition of the Chinese Population by Education</td>
<td>276</td>
</tr>
<tr>
<td>Table 2.9 Medical Institutions by Specialties and Affiliations</td>
<td>291</td>
</tr>
<tr>
<td>Table 2.10 Inpatient Beds of Medical Institutions by Specialties and Affiliations</td>
<td>291</td>
</tr>
<tr>
<td>Table 2.11 Medical Institutions by Ownership Type</td>
<td>293</td>
</tr>
<tr>
<td>Table 2.12 Inpatient Beds of Medical Institutions by Ownership Type</td>
<td>293</td>
</tr>
<tr>
<td>Table 2.13 Inpatient Beds of Medical Institutions by Hospital Grade</td>
<td>293</td>
</tr>
<tr>
<td>Table 2.14 Number of Medical Institutions by Grade in 2012</td>
<td>294</td>
</tr>
<tr>
<td>Table 2.15 Regional Population Distribution in China 1990-2014</td>
<td>294</td>
</tr>
<tr>
<td>Table 2.16 Regional Distribution of Medical Institutions and Inpatient Beds in 2014</td>
<td>295</td>
</tr>
<tr>
<td>Table 2.17 Regional Distribution of Healthcare Professionals in 2014</td>
<td>296</td>
</tr>
</tbody>
</table>
Table 2.18 Distribution of Inpatient Beds by Medical Specialty 2005-2012..............298
Table 2.19 Distribution of Physicians by Medical Specialty 2000-2012..................298
Table 2.20 Healthcare Personnel in China 1990-2015.........................................299
Table 2.21 Distribution of Healthcare Professionals in Cities & Counties 1990-2015..299
Table 2.22 Makeup of Healthcare Expenditures in China between 1980 and 2015 ....329
Table 2.23 Coverage/Finance of New Rural Cooperative Medical System (MRCMS) 336
Table 2.24 Overview of Medical Assistance Coverage in Urban & Rural Areas ........341
Table 2.25 Coverage of Chinese Population by Basic Medical Insurance (Mln) .......350
Table 2.26 Coverage and Finance of Urban BMI Programs ....................................350
Table 2.27 Coverage/ Finance of New Rural Cooperative Medical System ...............350
Table 2.28 NEDL Product Definition Change: 2012 Ed. vs. 2009 Ed. ....................386
Table 2.29 NEDL Structural Changes: 2012 Ed. vs. 2009 Ed. ..........................386
Table 2.30 NEDL Changes by WM Therapeutic Classes: 2012 Ed. vs. 2009 Ed. ....387
Table 2.31 NEDL Changes by TCM Therapeutic Classes: 2012 Ed. vs. 2009 Ed ..........387
Table 2.32 112 Added Drugs (Chemical Drugs & Biologicals) in NEDL 2012 Ed. ......388
Table 2.33 Chemical Drugs with Added/Reduced Routes/Forms in NEDL 2012 Ed....389
Table 3.1 Growth of Drug Consumption in China 2001-2015.................................403
Table 3.2 Growth of Healthcare Expenditures in China 1980-2015.........................403
Table 3.3 Rising Share of Per Capita Drug Expenditures in Healthcare..................406
Table 3.4 Percentage of Population Living in Urban / Rural Environrs ..................409
Table 3.5 Leading Diseases by Two-week Morbidity in 2003...............................414
Table 3.6 Leading Diseases by Two-week Morbidity in 2008..............................414
Table 3.7 Morbidity Rate of Chronic Diseases in 2003 and 2008 .........................415
Table 3.8 Trend of Top 10 Diseases for Inpatients of Urban Hospitals 2000-2012.....416
Table 3.9 Top 10 Diseases among Inpatients of County Level Hospitals 2000-2012..416
Table 3.10 Leading Causes of Death in Certain Regions of China in 2012.............418
Table 3.11 Leading Causes of Death among Chinese Males in 2012....................418
Table 3.12 Leading Causes of Death among Chinese Females in 2012..................419
Table 3.13 Examples of Drugs Covered under 2009 NRDL .............................................. 444
Table 3.14 Drugs Covered under Pap Program in China 2011 ........................................ 444
Table 3.15 Composition of Medical Care Providers in China 1950-2015 .................. 456
Table 3.16 No. of Outpatient Visits & Inpatients in Medical Institutions 1980-2015 ... 457
Table 3.17a Outpatient Visits & Inpatients by Medical Institution Type in 2013-2015 458
Table 3.17b Outpatient Visits and Inpatients by Medical Institution Type in Q1/2016. 459
Table 3.17c Regional Distribution of Outpatient Visits and Inpatients in Q1/2016 ...... 459
Table 3.18 No. of Outpatient Visits and Inpatients by Medical Specialties in 2012 .... 460
Table 3.19 No. of Outpatient & Emergencies Visits by Medical Specialties 2011-12 .. 461
Table 3.20a Average Days of Hospitalization 1985-2012.................................................. 461
Table 3.20b Occupancy Rate and Average Days of Hospitalization by Hospital Type 2013-2015 ..................................................................................................................... 462
Table 3.20c Regional Distribution of Medical Institutions and Inpatient Beds in 2016 462
Table 3.21 Income & Expenditure of Hospitals in 2012 ..................................................... 463
Table 3.22 Per Capita Outpatient Medical Expense in Public Hospitals 2007-2012..... 463
Table 3.23 Per Capita Inpatient Medical Expense in Public Hospitals ...................... 464
Table 3.24 Per Capita Outpatient Medical Expense in Health Sector General Hospitals ................................................................. 465
Table 3.25 Per Capita Inpatient Medical Expense in Health Sector General Hospitals 467
Table 3.26 Outpatient and Inpatient Healthcare Expenditures in China 2009-2012 ..... 468
Table 3.27a Medical Institution Drug Consumption by Facility Type 2010-2014 .... 471
Table 3.27b Medical Institution Drug Consumption by Facility Type 2007-2015 .... 472
Table 3.28 Top 10 Drug Products by Chinese Hospital Sales in 2015 ..................... 472
Table 3.29 Top 10 Systemic Anti-infectives Drugs in 2015 ........................................... 473
Table 3.30 Top 10 Anticancers & Immuno-Regulators in 2015 ................................. 474
Table 3.31 Top 10 Digestive System and Metabolism Drugs in 2015 ....................... 474
Table 3.32 Top 10 Blood and Blood Making System Drugs in 2015 ..................... 475
Table 3.33 Top 10 Nervous System Drugs in 2015 ....................................................... 475
Table 3.34 Top 10 Cardiovascular Drugs in 2015....................................................... 476
Table 3.35 Top 20 WMs in Chinese Urban Hospitals 2014-2015E ............................. 476
Table 3.36 Top 20 WM Brands in Chinese Urban Hospitals 2014-2015E ..................... 477
Table 3.37 Top 20 FTCMs in Chinese Urban Hospitals 2014-2015E ......................... 478
Table 3.38 Top 20 FTCM Brands in Chinese Urban Hospitals 2014-2015E ................. 479
Table 3.39 Top 10 Drug Suppliers by Quarterly Sales to Rep Urban Hospitals 2015 ... 480
Table 3.40 Top 10 Domestic Drug Suppliers to Chinese Hospitals 2015 ...................... 481
Table 3.41 Top 20 Companies by Hospital Drug Consumption Value in 2015 .......... 481
Table 3.42 Top 20 WM Suppliers to Chinese Urban Hospitals 2014-2015E ................. 482
Table 3.43 Top 20 FTCM Suppliers to Chinese Urban Hospitals 2014-2015E ............... 483
Table 3.44 Suppliers of Top 20 Chemical Drugs by Sales to Urban Public Hospitals 2014 ............................................................................................................. 484
Table 3.45 Top 20 Chemical Drug Suppliers by Sales to County Level Public Hospitals 2014 ............................................................................................................. 484
Table 3.46 Top 20 Chemical Drug Suppliers by Sales to CHCs 2014 ......................... 485
Table 3.47 Top 20 Chemical Drug Suppliers by Sales to Township Health Centers 2014 ............................................................................................................. 485
Table 3.48 Top 10 TCs in Rep Hospitals of Major Cities Q4/2015 ............................. 486
Table 3.49 TC Composition of Urban Hospital Drug Sales in 2014 and 2015E .... 487
Table 3.50 TC Composition of Urban Hospital Drug Sales 2015E: WMs vs. FTCMs . 487
Table 3.51 TC Structure of Chinese Hospital Drug Market in 2015 ......................... 488
Table 3.52 Changing Hospital Drug Consumption Patterns 2006-2013 ................... 488
Table 3.53 Medical Institution Chemical Drug Consumption Patterns 2014 ........ 489
Table 3.54 Top Ten Anticancers by Rep Hospital Consumption in 3Qs/2015 .......... 491
Table 3.55 Rep Hospital Consumption of Anticancers and Immuno-suppressants in Major Cities 2007-2015E ................................................................. 491
Table 3.56 Anticancer Drug Market Trend by Sub-TCs in Rep Hospitals 2013-2014 .. 491
Table 3.57 Rep Hospital Consumption of Small Molecule Target-oriented Anticancers in Major Cities 2006-2015E ................................................................. 492
Table 3.58 Icotinib Rep Hospital Consumption in Major Cities 2011-2015E .......... 492
Table 3.59 Imatinib Rep Hospital Consumption in Major Cities 2007-2014 .......... 492
Table 3.60 Small Molecule Target-oriented TKIs Drugs Approved by CFDA ........493
Table 3.61 Diabetes Drug Market Trend by Sub-TCs in Rep Hospitals 2013-2014 .....497
Table 3.62 China Insulin Market 2015 .................................................................500
Table 3.63 Leading Players of Insulin & Analogues in China 2015.......................500
Table 3.64 Cardiovascular Drugs Consumption in Rep Hospitals of 22 Chinese Cities 2005-2015E.................................................................501
Table 3.65 Rep Hospital Consumption of Hepatic Drugs in Major Cities 3Qs/2015 ....502
Table 3.66 Rep Hospital Consumption of Hepatic Drugs in Major Cities 2011-2015..502
Table 3.67 Top 10 Hepatic Drugs by Rep Hospital Consumption in 3Qs/2015 ........502
Table 3.68 Top 10 Rep Hospital Suppliers of Hepatic Drugs in 3Qs/2015 ...............502
Table 3.69 Respiratory System Chemical Drugs in Public Hospitals 2006-2014 ........505
Table 3.70 Top 10 Anti-asthma Chemical Drugs in Chinese Hospitals 2014............506
Table 3.71 LRA and Theophylline Consumption in Chinese Hospitals 2006-2014 .....506
Table 3.72 Representative LRA and Theophylline Drugs in Chinese Hospitals .......506
Table 3.73 Statistical Summary of Chinese Senior Population ................................509
Table 3.74 Geriatric Drugs in Major Cities Public Hospitals 2011-2014.....................510
Table 3.75 Growth of County Level Hospital Drug Market in Six Provinces............511
Table 3.76 Shares of County Level Hospital Drug Market in Six Provinces ..........512
Table 3.77 MNC Market Share in Urban and County Level Hospitals 2009-2015 .....513
Table 3.78 Top 10 TCs in Chinese County Level Hospitals M10/2015 ....................514
Table 3.79 Top 10 Drug Suppliers to Chinese County Level Hospitals M10/2015 ......514
Table 3.80 Shares of MNC/Local Cos in County Level Hospitals of Six Provinces M10/2015 ........................................................................515
Table 3.81 Top 10 Drug Suppliers to County Level Hospitals in Six Chinese Provinces M10/2015 ........................................................................515
Table 3.82 Top 10 Products in Chinese County Level Hospitals M10/2015 ..........516
Table 3.83 TC Composition of County Level Hospital Drug Market 2014-2015E ....517
Table 3.84 TC Composition of Chinese County Level Hospital Drug Market 2014-2015E: WMs vs. TCMs ........................................................................517
Table 3.85 Top 20 WMs of Chinese County Level Hospitals 2014-2015E ..........518
Table 3.86 Top 20 WM Brands of Chinese County Level Hospitals 2014-2015E ........519
Table 3.87 Top 20 FTCMs of Chinese County Level Hospitals 2014-2015E.............520
Table 3.88 Top 20 FTCM Brands of Chinese County Level Hospitals 2014-2015E.....520
Table 3.89 Top 20 WM Suppliers to County Level Hospitals 2014-2015E...............522
Table 3.90 Top 20 FTCM Suppliers to County Level Hospitals 2014-2015E..........522
Table 3.91 Number and Distribution of Medical Facilities in China 2014..............523
Table 3.92 County Level Public Hospitals Drug Consumption 2010-2014............523
Table 3.93 Medical Institution Drug Consumption by Facility Type 2010-2014 ....524
Table 3.94 Medical Institution Chemical Drug Consumption Patterns 2014 ..........524
Table 3.95 Top 10 Anti-infectives in County Level Public Hospitals 2014...........525
Table 3.96 Top 10 Digestive System and Metabolism Drugs in County Level Public Hospitals 2014 .................................................................525
Table 3.97 Top 10 Blood & Blood-making System Drugs in County Level Public Hospitals 2014 ..................................................................................525
Table 3.98 Top 15 Provinces by Patient Visit Share in CHCs 2014.......................526
Table 3.99 Growth of Drugs Sales Value in Tier 1 Cities 2015: Hospitals VS. CHCs ..527
Table 3.100 Top 5 TCs by Sales Value 2015: Hospitals VS. CHCs .....................527
Table 3.101 Top 10 Suppliers to Tier 1 City CHCs by Sales Value 2015 ..............527
Table 3.102 Top 10 Products in Tier 1 City CHCs by Sales Value 2015 .............528
Table 3.103 TC Composition of Drug Consumption by Urban CHCs 2014-2015E....529
Table 3.104 TC Composition of Drug Consumption by Urban CHCs 2014-2015E: WMs vs. TCMs ..........................................................529
Table 3.105 Top 20 WMs in Urban CHCs 2014-2015E ..................................530
Table 3.106 Top 20 WM Brands in Urban CHCs 2014-2015E..........................530
Table 3.107 Top 20 FTCMs in Urban CHCs 2014-2015E..............................531
Table 3.108 Top 20 FTCM Brands in Urban CHCs 2014-2015E......................532
Table 3.109 TC Composition of Drug Consumption by Chinese Township Health Centers 2014-2015E .................................................................533
Table 3.110 TC Composition of Drug Consumption by Chinese Township Health Centers 2014-2015E: WMs vs. TCMs ........................................533
Table 3.111 Top 20 WMs of Chinese Township Health Centers 2014-2015E ............... 534
Table 3.112 Top 20 WMs of Chinese Township Health Centers 2014-2015E .......... 534
Table 3.113 Top 20 FTCMs of Chinese Township Health Centers 2014-2015E ...........535
Table 3.114 Top 20 FTCM Brands of Chinese Township Health Centers 2014-2015E 536
Table 3.115 Number of Chinese Retail Pharmacy Outlets 2012-2015 ....................... 537
Table 3.116 Sales of Top 100 Chinese Retail Pharmacy Chains 2010-2014 .............. 537
Table 3.117 Urban Retail Pharmacy Market Segmentation by Sectors 2015 .............. 540
Table 3.118 OTC and Health Food Sales of Chinese Retail Pharmacies 2015 .......... 540
Table 3.119 Chinese Retail Pharmacy Market 2009-2015E: Non-Drugs vs. Drugs ..... 542
Table 3.120 Composition of Chinese Retail Market Sales of Non-drugs 2011-2015E . 542
Table 3.121 Chinese Retail Pharmacy Drug Sales 2011-2015E: WMs vs. TCMs ....... 543
Table 3.122 Chinese Retail Pharmacy Sales 2011-2015E: OTC vs. Rx ..................... 543
Table 3.123 Top 10 Chemical Drug TCs by Chinese Hospital Drug Consumption H1/2014-H1/2015 ................................................................. 543
Table 3.124 Top 10 TCM TCs in Chinese Retail Pharmacy Market H1/2014-H1/2015544
Table 3.125 20 TCs of Chinese Retail Pharmacy Drug Sales 2014-2015E ............... 545
Table 3.126 Top 10 TCs of Chinese Retail Pharmacy Sales of WMs 2014-2015E...... 546
Table 3.127 Top 10 TCs of Chinese Retail Pharmacy Sales of TCMs 2014-2015E..... 546
Table 3.128 Top 10 Categories by Sales Value in Retail Drugstores H1/2015 .......... 547
Table 3.129 Top 10 TCs by Sales Growth in Retail Drugstores H1/2015 .............. 547
Table 3.130 Top 20 Drug Brands by Chinese Retail Pharmacy Sales MAT Q2/2013... 548
Table 3.131 Top 20 WMs by Chinese Retail Pharmacy Sales 2014-2015E .......... 549
Table 3.132 Top 10 FTCMs by Chinese Retail Pharmacy Sales 2014-2015E ........... 550
Table 3.133 Top 10 Cold Drugs by Chinese Retail Sales in 2014 .......................... 550
Table 3.134 Top 10 Antibiotics Drugs Shares by Chinese Retail Sales in 2014 ...... 551
Table 3.135 Top 10 Vitamin Products by Chinese Retail Sales in 2014 ................. 551
Table 3.136 Top 10 Gastrointestinal Drugs by Chinese Retail Sales in 2014 .......... 552
Table 3.137 Top 10 Cardio-/Cerebro-vascular Drugs by Chinese Retail Sales in 2014 552
Table 3.138 Top 10 Cough Drugs by Chinese Retail Sales in 2014 ........................ 553
Table 3.139 Top 10 Skin Disease Drugs by Chinese Retail Sales in 2014 .................553
Table 3.140 Top 10 Anti-hypertension Drugs by Chinese Retail Sales in 2014 ..........554
Table 3.141 Top 10 Gynecological Drugs by Chinese Retail Sales in 2014 ..........555
Table 3.142 Top 10 Throat Medicines by Chinese Retail Sales in 2014 ..........555
Table 3.143 Top 20 Drug Suppliers to Chinese Retail Pharmacies 2014-2015E ..........556
Table 3.144 Top 10 Players by Chinese Retail Pharmacy Sales 3Qs/2013-3Qs/2014 ....557
Table 3.145 Chinese Pharma B2C Market Size and Forecast 2011-2017 ...............558
Table 3.146 Overall and Online Chinese Prescription Drug Sales 2014-2020 ..........558
Table 3.147 Structure of Chinese Pharma B2C Market in 2014 (1) .......................558
Table 3.148 Structure of Chinese Pharma B2C Market by Subsectors 2015 (2) .......559
Table 3.149 Performance of TMall Pharmacy Portal 2012-2015 .......................559
Table 3.150 Top Ten Online Pharmacies by Sales Value 2015 ..........................559
Table 3.151 Gross Profit Margins and Expense Ratio of Pharma B2C Sector 2015 ....559
Table 3.152 Expenditure Composition of Chinese Pharma B2C Sector 2015 ..........560
Table 3.153 Growth of Chinese Online Pharmacy Sales 2010-2015E ..................560
Table 3.154 Composition of Chinese Online Pharmacy Sales in 2014 ..................560
Table 3.155 Top 10 TCs of Chinese Online Pharmacy Drug Sales 2014 ...............561
Table 3.156 Chinese OTC Drug Market by Therapeutic Subclasses 2014-2015 ....562
Table 3.157 Top 10 TCs by Chinese Retail Pharmacy OTC Drug Sales 2015 ..........564
Table 3.158 Top 10 OTC Drug Brands and Suppliers by Retail Pharmacy Sales 2015 565
Table 3.159 Top 10 OTC Suppliers to Chinese Retail Pharmacies 2015 ...............565
Table 3.160 Top 20 OTC & Health Food Players in Retail Pharmacy Market 2015 .......566
Table 3.161 Top 20 OTC & Health Products in China Retail Market 2015 .............566
Table 3.162 China's Top 5 OTC Chemical Drug Brands in 2015 .......................567
Table 3.163 Top 10 Formulated TCMs by Chinese Hospital Sales (May 2013) ....578
Table 3.164 Composition of Chinese Pharma Market 2012: TCMs vs. WMs ........579
Table 3.165 Hospital Market Share of Formulated TCMs by TCs 2012 ...............579
Table 3.166 Market Share of Formulated TCMs by Hospital Tier 2012 ...............579
Table 3.167 Formulated TCMs under NRDL 2000 Ed. & 2009 Ed. .......................... 580
Table 3.168 Share of Formulated TCMs in Total NRDL Reimbursement 2010 ............... 580
Table 3.169 Share of NEDL FTCMs in Chinese FTCM Sales Value by TCs in 2012 ............ 580
Table 3.170 Composition of Urban Hospital TCM Consumption 2014 .......................... 581
Table 3.171 TCM Consumption by TCs in Public Medical Institutions 2014 ..................... 582
Table 3.172 Top 20 TCM Drugs in Urban Public Hospitals 2014 ................................. 582
Table 3.173 Top 20 TCM Drugs in County Level Public Hospitals 2014 ......................... 583
Table 3.174 Top 20 TCM Drugs in Community Health Service Centers 2014 ................... 583
Table 3.175 Top 20 TCM Drugs in Township Health Centers 2014 ............................... 584
Table 3.176 Top 20 TCM Suppliers by Sales to Urban Public Hospitals 2014 .................. 585
Table 3.177 Top 20 TCM Suppliers by Sales to County Level Public Hospitals 2014 ...... 585
Table 3.178 Top 20 TCM Suppliers by Sales to CHCs 2014 ........................................ 586
Table 3.179 Top 20 TCM Suppliers by Sales to Township Health Centers 2014 .............. 587
Table 3.180 Changing Hospital TCM Drug Consumption Patterns Since 2006 .............. 587
Table 3.181 Chinese TCM Market Segmentation 2013-2015 ....................................... 588
Table 3.182 Chinese Drug Market Size by Major Segments 2014-2015E ....................... 590
Table 3.183 Growth of Chinese Hospital Drug Sales by City Level in 2014-2015 ............. 591
Table 3.184 2015 Hospital Drug Sales Growth in 24 Provinces .................................... 591
Table 3.185 Structure of Provincial Level Hospital Drug Markets in China 3Qs/2015 ...... 593
Table 3.186 Growth of Provincial Level Hospital Drug Markets ..................................... 594
Table 3.187 Rx Number and Value in Shanghai General Hospitals 2015 ..................... 594
Table 3.188 Growth of Rx No. and Value in Shanghai General Hospitals 2015 (1) ....... 595
Table 3.189 Growth of Rx No. and Value in Shanghai General Hospitals 2015 (2) ...... 595
Table 3.190 Average Inpatient Per Visit Expenses in Shanghai General Hospitals .......... 595
Table 3.191 Share and Growth of Top 3 TCs in Shanghai Level 2 General Hospitals 2015 .............................................................. 595
Table 3.192 Shares and Growth of Top 3 TCs in Shanghai Level 3 General Hospitals 2015 ........................................................................ 596
Table 3.193 Regional Chinese Pharma Distribution Sales in 2015 ............................... 596
Table 3.194 Regional Pharmaceutical Distributor Sales Structure 2015 .......................... 597
Table 3.195 Regional Pharmaceutical Distributor Sales Structure 2014 .......................... 598
Table 3.196 Regional Distribution of Chinese Retail Pharmacy Outlets 2014 .................. 599
Table 3.197 Number of Urban Retail Pharmacies by City Tiers 2012 & 2014 .................. 599
Table 3.198 Growth of Urban Retail Pharmacy Sales by City Tier 2015 ...................... 599
Table 3.199 Retail Pharmacy Market Segmentation by Level 2015 ............................. 600
Table 3.200 Retail Pharmacy Market Segmentation by Level 2015 ............................. 600
Table 3.201 Leading Provincial Level Retail Pharmacy Markets ................................. 600
Table 3.202 Chinese Retail OTC Drug Consumption Value by City Tier 2012 ........... 602
Table 3.203 Top 10 TCs by Share of Rx Value and No. in Shanghai Rep CHCs 2013 . 604
Table 3.204 Top 10 Sub-TCs by Rx Value Share and Growth in Shanghai CHCs 2013605
Table 3.205 Top 10 Drugs by Rx Value Share and Growth in Shanghai Rep CHCs 2013 .......... 605
Table 3.206 Top 10 NEDL Products in Shanghai Rep CHCs in 2013 ......................... 606
Table 3.207 Hospital Market Shares of Local, JV and Imported Drugs 2006-2015 .... 608
Table 3.208 Quarterly Growth Rates in 2015: MNCs vs. Domestics .......................... 608
Table 3.209 Chinese Hospital Drug Sales Growth Drivers 2014-2015 .......................... 608
Table 3.210 Hospital Growth by City Level in 2014-2015: Domestics vs. MNCs ....... 608
Table 3.211 Hospital Drug Sales in 24 Provinces 2015: Domestics vs. MNCs ............. 609
Table 3.212 Growth of County Level Hospital Drug Market in Six Provinces 2015: Domestics vs. MNCs .......................................................................................... 610
Table 3.213 Shares of County Level Hospital Drug Market in Six Provinces 2015: Domestics vs. MNCs .......................................................................................... 611
Table 3.214 Chinese Drug Market Segmentation 2013-2015: MNCs vs. Domestics (1) .................................................................................................................................. 612
Table 3.215 Chinese Drug Market Segmentation 2013-2015: MNCs vs. Domestics (2) .................................................................................................................................. 612
Table 3.216 Drug Consumption of Leading TCs in Level 3 General Hospitals 2015: Domestics vs. JVs vs. Foreign Cos ................................................................. 613
Table 3.217 Drug Consumption of Leading TCs in Level 2 General Hospitals 2015: Domestics vs. JVs vs. Foreign Cos ................................................................. 613
| Table 3.218 Supplier Structure of Level 3 Chinese General Hospitals 2015 .................. 613 |
| Table 3.219 Supplier Structure of Level 2 Chinese General Hospitals 2015 .................. 613 |
| Table 3.220 Leading Suppliers of Major TCs in Level 3 General Hospitals 2015 .......... 614 |
| Table 3.221 Leading Suppliers of Major TCs in Level 2 General Hospitals 2015 ........ 614 |
| Table 4.1 # of Pharma Manufacturers 2011-2015 .................................................. 636 |
| Table 4.2 # of Pharma Distribution License Holders 2013-2015 ............................... 636 |
| Table 4.3 # of Retail Pharmacy Chain Companies 2011 – 2015 ............................... 636 |
| Table 4.4 # of Retail Pharmacy Stores 2011 – 2015 .................................................. 637 |
| Table 4.5 # of Protected TCM Products 2013-2015 .................................................. 637 |
| Table 4.6 Overview of All Registration Applications in 2011-2015 .......................... 638 |
| Table 4.7 Number of Drug Registration Applications under CDE Review 2009-2015 .... 638 |
| Table 4.8 Breakdown of Drug Registration Applications under CDE Review in 2015 ... 638 |
| Table 4.9 Chemical Drug Registration Applications Accepted by CDE in 2011-2015 .... 639 |
| Table 4.10 ANDAs with Excessive Duplicate Applications Pending Review 2015 ....... 639 |
| Table 4.11 Chemical Drug Validation CTAs Pending CDE Review in 2015 ................. 640 |
| Table 4.12 Breakdown of Registration Applications with Completed CDE Review in 2015 .......................................................... 640 |
| Table 4.13 Breakdown of CDE Recommended Drug Clinical Trial Approvals in 2015 ..... 641 |
| Table 4.14 Breakdown of CDE Recommended Drug Launch Approvals in 2015 ........... 641 |
| Table 4.15 Breakdown of CDE Recommendations for Chemical Drug Applications in 2015 .................................................................................................................. 641 |
| Table 4.16 # of Concluded Chemical Drug Registration Applications by the CDE in 2012-2015 ................................................................................................................. 642 |
| Table 4.17 TCM Registration Applications Accepted by the CDE in 2012-2015 .......... 642 |
| Table 4.18 Breakdown of CDE Recommendations for TCM Registration Applications in 2015 .................................................................................................................. 642 |
| Table 4.19 # of Concluded TCM Registration Applications by the CDE in 2012-2015 .... 643 |
| Table 4.20 Biological Product Registration Applications Accepted by the CDE in 2012-2015 ................................................................................................................. 643 |
| Table 4.21 Breakdown of CDE Recommendations for Biological Product Applications in |
Table 4.22 # of Concluded Biological Product Registration Applications by the CDE in 2012-2015 ................................................................. 644
Table 4.23 Important Product Approvals in 2015 ........................................ 644
Table 4.24 Pharma-related Regulatory Introductions in China in 2012-2015 and H1/2016  .......................................................................................... 646
Table 4.25 Pharma-related Regulations and Policies Newly Issued in H1/2016 ........ 646
Table 4.26 Quarterly Pharma-Related Regulatory Introductions in China 2011– 2015 648
Table 4.27 New Pharma-Related Regulations and Policies Issued in 2015 (1) .......... 648
Table 4.28 New Pharma-Related Regulations and Policies Issued in 2015 (2) .......... 649
Table 4.29 New Classification System for Registration and Exclusivity of Chemical Drugs .......................................................................................................... 712
Table 5.1 Overall Chinese Drug Market Size and Growth 2007-2015E .................. 990
Table 5.2a Chinese Drug Market Size by Sub-segments 2007-H1/2015(1) ............... 991
Table 5.2b Chinese Drug Market Size by Sub-segments 2010-H1/2015(2) ............... 992
Table 5.3 Chinese Drug Market Shares by Sub-segments 2012-H1/2015 ................. 992
Table 5.4 Composition of Medical Institution Drug Consumption 2014 ................. 992
Table 5.5 Growth of Chinese Pharmaceutical Market by Channels in 2013-2015 ...... 993
Table 5.6 Chinese Hospital Drug Market 2011-2015 ............................................. 993
Table 5.7 CAGR Growth of Chinese Hospital Market 2011-2015 ......................... 993
Table 5.8 MAT Quarterly Growth of Chinese Hospital Drug Market in 2015 .......... 994
Table 5.9 Chinese Drugs Market Segmentation 2009-2015 by Value (CNY bln) ...... 995
Table 5.10 Chinese Drugs Market Segmentation 2010-2015 by Growth (%) .......... 996
Table 5.11 Chinese Drugs Market Segmentation 2009-2015 by Market Share (%) ...... 996
Table 5.12 Chinese Drug Market Segmentation 2013-3015 by Value: OTC vs. RX .... 996
Table 5.13 Chinese Drug Market Segmentation 2013-2015 by Market Share: OTC vs. RX  ........................................................................................................ 997
Table 5.14 Chinese Drug Market Segmentation 2013-2015 by Value: Chemical Drugs vs. FTCMs ......................................................................................... 997
Table 5.15 Chinese Drug Market Segmentation 2013-2015 by Market Share: Chemical
Drugs vs. FTCMs................................................................. 997
Table 5.16 China Pharma Market Size and Growth 2010-2014 .................. 998
Table 5.17 Structure of Chinese Pharma Market in 2014 ......................... 998
Table 5.18 Total Chinese Healthcare Expenditures 2010-2014 .................. 998
Table 5.19 Chinese Broad Healthcare Market in 2014 .......................... 999
Table 5.20 Chinese Pharma Industry Revenues by Subsectors 2015 ............ 1000
Table 5.21 Chinese Pharma Industry Profits by Subsectors 2015 ................ 1000
Table 5.22 Revenues and Profits of Chinese Pharma 2010-2016E .............. 1001
Table 5.23 Forecasts of Chinese Pharma Revenues and Profits by Subsectors 2016.. 1001
Table 5.24 Growth of Chinese Pharma Industrial Value Added vs. GDP .......... 1002
Table 5.25 Chinese Foreign Trade of Medicines and Health Products in 2015 .... 1004
Table 5.26 Chinese Foreign Trade of Medicines and Health Products 2009-2015 ..... 1004
Table 5.27 Chinese Export of Medicines and Health Products 2015 ............ 1004
Table 5.28 Regional Export Markets for Chinese MHPs in 2015 .................. 1005
Table 5.29 Top 10 Export Markets of Chinese MHPs in 2015 ...................... 1005
Table 5.30 Leading Exporters for Chinese MHPs by Ownership Type in 2015..... 1006
Table 5.31 Chinese Import Markets of Medicines and Health Products 2015 .... 1006
Table 5.32 Regional Origins for Chinese Import of MHPs in 2015 ................ 1007
Table 5.33 Top 10 Country Origins for Chinese Import of MHPs in 2015 .......... 1007
Table 5.34 Leading Import Companies for Chinese MHPs by Properties in 2015.... 1007
Table 5.35 Top 10 Chinese WMs Exporters in 2015 .................................. 1008
Table 5.36 Top 10 Chinese APIs Exporters in 2015 .................................. 1008
Table 5.37 Top 10 Chinese Pharma Formulations Exporters in 2015 .............. 1008
Table 5.38 Top Ten Pharma MNCs in China 2015 .................................... 1042
Table 5.39 Summary of Chinese Pharma Events Q2/2016 and H1/2016 .......... 1056
Table 5.40 Summary of Sino-foreign Licensing Deals in H1/2016 (1) ............ 1057
Table 5.41 Summary of Sino-foreign Licensing Deals in H1/2016 (2) ............ 1058
Table 5.42 Summary of Selected JV/Strategic Alliance Deals in H1/2016 (1) .... 1059
Table 5.43 Summary of Selected JV/Strategic Alliance Deals in H1/2016 (2)...........1060
Table 5.44 Summary of Sino-foreign M&A Deals in H1/2016 .................................1061
Table 5.45 Summary of Sino-foreign CR/Collaborative R&D Agreements H1/2016 .1062
Table 5.46 Summary of Chinese Pharma Events in 2011 - 2015 ............................1063
Table 5.47 Summary of Sino-foreign Licensing Deals in 2015 (1) ............................1063
Table 5.48 Summary of Sino-foreign Licensing Deals in 2015 (2) ............................1064
Table 5.49 Summary of Sino-foreign Licensing Deals in 2015 (3) ............................1065
Table 5.50 Summary of Sino-foreign Licensing Deals in 2015 (4) ............................1066
Table 5.51 Summary of Sino-foreign M&A Deals in 2015 (1).................................1067
Table 5.52 Summary of Sino-foreign M&A Deals in 2015 (2).................................1068
Table 5.53 Summary of Selected Sino-foreign JV/Strategic Alliance Deals in 2015 (1) ..................................................................................................................1069
Table 5.54 Summary of Selected Sino-foreign JV/Strategic Alliance Deals in 2015 (2) ..................................................................................................................1070
Table 5.55 Summary of Sino-foreign CR/Collaborative R&D Agreements in 2015 (1) ..................................................................................................................1071
Table 5.56 Summary of Sino-foreign CR/Collaborative R&D Agreements in 2015 (2) ..................................................................................................................1072
Table 5.57 IMS Forecast of Chinese Pharma Market in 2011-2020..........................1077
Table 5.58 Chinese Drug Market Size and Growth 2009-2017E...............................1078
Table 6.1 Selected Outbound Sino-foreign Licensing Deals in 2015 and 2016...........1169
Table 6.2 Indigenously-developed Class I New Chemical Drugs (Production License) 2006-2013.................................................................................................1182
Table 6.3 Indigenously-developed Class I New Biologics (Production License) 2006-2013 .................................................................................................1182
Table 6.4 Indigenously-developed Class I New Drugs (New Drug Certificates) 2006-2013 .................................................................................................1183
Table 6.5 Time Required for Registration of Class 1.1 New Drugs in China ..........1183
Table 6.6 Class 1 New Drugs Approvals in 2003-2015 ............................................1184
Table 6.7 Class 1 New Drug Applicants by Ownership 2003-2015........................1184
Table 6.8 Class 1 New Drug Applicants by Company Size 2003-2015...............1184
Table 6.9 Class 1 New Drug Applicants by Stock Listing 2003-2015 ................. 1184
Table 6.10 Class 1 New Drug Approvals by # of Producers 2003-2015 ................. 1185
Table 6.11 Approved Class 1 New Drugs by Indications 2003-2015 ....................... 1185
Table 6.12 Total New Anti-cancer Chemical Drugs Applications in China 2014 ...... 1186
Table 6.13 Class 1.1 & 3.1 New Anti-cancer Chemical Drugs Applications in China 2014 ................................................................. 1186
Table 6.14 New Class 1.1 Anti-cancers Drugs Applications in China 2014............ 1186
Table 6.15 Applications for New Tinib Class of Anticancers in China 2014 ............ 1187
Table 6.16 Drug Applications on Special Approval Path 2004-2015 ......................... 1188
Table 6.17 Drug Applications on Special Approval Path 2004-2015: Local vs. Import ................................................................. 1188
Table 6.18 Structure of Drug Applications on Special Approval Path 2004-2015..... 1189
Table 6.19 Drug Applications on Special Approval Path by Indications 2015......... 1189
Table 6.20 Top Applicants by # of Drug Applications on Special Approval Path in 2015 ........................................................................................................................................ 1189
Table 6.21 Drug Registration Applications on Fast Tracks 2011-2014: Domestic vs. Import .......................................................................................................................................................................................... 1191
Table 6.22 Applications on Fast Drug Registration Tracks 2011-2014: Top Applicants .......................................................................................................................................................................................... 1191
Table 6.23 Number of Recorded New Drug Projects in China in 2012- H1/2016 ...... 1192
Table 6.24 Chinese New Drug Projects by R&D Phase in 2012-2015 and H1/2016.. 1192
Table 6.25 Summary of Chinese New Drug Projects Recorded in H1/2016.......... 1192
Table 6.26 Number of Recorded Novel New Drug Projects in China in 2011 - 2015. 1193
Table 6.27 Chinese New Drug Projects by R&D Phase in 2010 - 2015............... 1194
Table 6.28 Summary of Chinese New Drug Projects Recorded in 2015 (1) .......... 1194
Table 6.29 Summary of Chinese New Drug Projects Recorded in 2015 (2) ............ 1195
Table 6.30 Summary of Chinese New Drug Projects Recorded in 2015 (3) ............ 1196
Table 7.1 Chinese Pharma B2C Market Size and Forecast 2011-2017 ................. 1361
Table 7.2 Structure of Chinese Pharma B2C Market in 2014 (1) ......................... 1362
Table 7.3 Structure of Chinese Pharma B2C Market in 2014 (2) ......................... 1362
Table 7.4 Companies with Type A Pharma e-Commerce Certificates as of 03/2015 ........................................ 1362
Table 7.5 Top 20 Online Pharmacies by Sales Value 2014-2015 ................................................................. 1363
Table 7.6 Top 20 Online Pharmacy by Sales Value on TMall Platform 2014 .............................................. 1363
Table 7.7 Anticipation of Mobile Health Development in China ................................................................. 1373
Table 7.8 Mobile Health Will Change the Way People Acquire Medical Info ........................................ 1373
Table 7.9 Purposes of Mobile Health Purchases .......................................................................................... 1374
Table 7.10 Anticipated Leading Application Centers of Mobile Health Products ..................................... 1374
Table 7.11 Leading Issues of Mobile Health Products ................................................................................ 1374
Table 7.12 Perceived Reasonable Pricing of Mobile Health Hardware ...................................................... 1375
Table 7.13 Feedbacks on Existing Prices of Mobile Health Products .......................................................... 1375
Table 7.14 Mobile Health APP Downloads by Respondents in 2014 ......................................................... 1375
Table 7.15 Reasonable Fee Structure of Mobile Health APPs ..................................................................... 1376
Table 8.1 Types of Clinical Research Participated by Respondents .......................................................... 1443
Table 8.2 # of Clinical Trials Participated by Respondents ......................................................................... 1444
Table 8.3 Understanding of WMA’s Helsinki Declaration ......................................................................... 1444
Table 8.4 Relevant Clinical Research Experience of Respondents ............................................................. 1444
Table 8.5 Origins of Clinical Research Knowledge of Respondents ............................................................ 1444
Table 8.6 Benefits of Clinical Research Perceived by Respondents ............................................................. 1444
Table 8.7 Barriers of Clinical Research Faced by Respondents .................................................................. 1445
LIST OF CHARTS

Chart 1.1 Gross Output Value of Broad Chinese Pharmaceutical Industry 2006 – 2015 89
Chart 1.2 Core Business Revenues of Broad Chinese Pharma Industry 2006 – 2016E .. 89
Chart 1.3 Pretax Profit Margin Trend of the Chinese Pharma Industry 1997-2015 ............ 90
Chart 1.4 Composition of Chinese Pharma Industry by Revenues in H1/2015 ............ 92
Chart 1.5 Revenues of Six Chinese Pharma Sub-sectors in H1/2015 .......................... 92
Chart 1.6 Net Profit of Chinese Pharmaceutical Industry 2006 – 2015 ........................ 93
Chart 1.7 Composition of Chinese Pharma Industry by Net Profits in H1/2015 ............... 93
Chart 1.8 Net Profit Growth of Six Chinese Pharma Sub-sectors in H1/2015 ................. 94
Chart 1.9 Revenues of Chinese Biologic Product Subsector 2006-2015 ........................ 112
Chart 1.10 Net Profit of Chinese Biologic Products Subsector 2006-2015 ...................... 113
Chart 1.11 Chinese Pharmaceutical Distribution Industry Performance 2007-2015 .... 120
Chart 1.12 Composition of Chinese Pharmaceutical Distributor Sales in 2015 ................. 121
Chart 1.13 Chinese Retail Pharmacy Market Segmentation in 2015 ......................... 122
Chart 1.14 Profit Margins of the Chinese Pharma Distribution Sector Since 2002 123
Chart 1.15 R&D Centers of RDPAC Members by Research Stage in China ................. 142
Chart 1.16 R&D Centers of RDPAC Members by Function in China .......................... 143
Chart 1.17 Locations of R&D Centers of RDPAC Members in China ......................... 143
Chart 1.18 Chinese Market Access by New Drugs – 1 Year After Launch ................. 144
Chart 1.19 Chinese Market Access by New Drugs – 2 Years after Launch .................. 145
Chart 1.20 Number of Chinese Retail Pharmacy Chains 2006-2015 ....................... 173
Chart 1.21 Number of Chinese Retail Pharmacy Stores 2006-2015 ...................... 173
Chart 1.22 Chinese Hospital Market Growth 2007-2015 ........................................ 217
Chart 1.23 Number of Chinese Retail Pharmacy Stores 2007-2015 ..................... 225
Chart 1.24 Structure of Retail Pharmacy Outlets Since 2006 ............................. 225
Chart 1.25 Number of Chinese Retail Pharmacy Chains Since 2006 ..................... 226
Chart 1.26 Number of Outlets Owned by Retail Pharmacy Chains Since 2006 .......... 226
Chart 1.27 Number of Independent Retail Pharmacy Stores Since 2006 ............... 227
Chart 4.8 Compulsory License Application Process

Chart 4.9 Application Procedures of APP

Chart 4.10 Flowchart – Revocation Procedures of APP

Chart 4.11 Re-examination Procedures of APP

Chart 4.12 Infringement Settlement Procedures of APP

Chart 5.1 Overall Chinese Drug Market Size and Growth 2007-2015E

Chart 6.1 Pharmaceutical Industry’s Expenditure on R&D

Chart 6.2 Supply Structure of Chinese Drug Manufacturers 2008/2014

Chart 6.3 Government Spending on R&D

Chart 7.1 Structure of the Chinese Pharma Distribution System in the Old Days

Chart 7.2 Hospital Distribution of the Respondents

Chart 7.3 Professional Title Distribution of the Respondents

Chart 7.4 No. of Conferences in Average Attended Annually (last two years)

Chart 7.5 Lengthen of Optimal Duration for an Academic Conference

Chart 7.6 Which Sponsors of Academic Conferences Are Most Trusted by You?

Chart 7.7 What Types of Meetings Do You Prefer to Attend?

Chart 7.8 The Major Purpose of Attending an Academic Event

Chart 7.9 Registration Fee Paid to Attend an Academic Conference?

Chart 7.10 Evaluation on Overall Situation of Domestic Academic Conferences

Chart 7.11 Any Areas for Improvement? (Check all that apply)

Chart 7.12 Top 10 Companies in Academic Marketing (All Physicians)

Chart 7.13 Top 10 Companies in Academic Marketing (Endocrinologists)

Chart 7.14 Top 10 Companies in Academic Marketing (Oncologists)

Chart 7.15 Online/Digital Platforms Attractive to Chinese Physicians

Chart 7.16 Top Five High Customer Loyalty Scores (All Physicians)

Chart 7.17 Top Five High Customer Loyalty Scores (Oncologists)

Chart 7.18 Approval Process of Hospital Drug Purchase

Chart 7.19 Hospital Market Potential Assessment Process
Chart 7.20 Pharmaceutical Distribution Channels in the Urban Areas .................. 1332
Chart 7.21 Pharmaceutical Distribution through Retail Pharmacies .................. 1332
Chart 7.22 Pharmaceutical Distribution in Sub-urban and Rural Areas .............. 1333
Chart 7.23 Dominant Distribution Models Used by MNCs in China ............... 1339
# TABLE OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADR</td>
<td>Adverse Drug Reaction</td>
</tr>
<tr>
<td>API</td>
<td>Active Pharmaceutical Ingredients</td>
</tr>
<tr>
<td>APP</td>
<td>Administrative Protection of Pharmaceuticals</td>
</tr>
<tr>
<td>AmCham</td>
<td>American Chamber of Commerce</td>
</tr>
<tr>
<td>CAGR</td>
<td>Compound Annual Growth Rate</td>
</tr>
<tr>
<td>CCCIEMHP</td>
<td>China Chamber of Commerce for Import &amp; Export of Medicines and Health Products</td>
</tr>
<tr>
<td>CAPC</td>
<td>China Association of Pharmaceutical Commerce</td>
</tr>
<tr>
<td>CFDA</td>
<td>China Food and Drug Administration (formerly State Food and Drug Administration or CFDA)</td>
</tr>
<tr>
<td>ChP</td>
<td>Chinese Pharmacopoeia</td>
</tr>
<tr>
<td>CMH</td>
<td>China Monitor Health</td>
</tr>
<tr>
<td>CNCM</td>
<td>China National Corporation of Medicines</td>
</tr>
<tr>
<td>CNY</td>
<td>Chinese Yuan</td>
</tr>
<tr>
<td>CPIIC</td>
<td>China Pharmaceutical Industry Information Center</td>
</tr>
<tr>
<td>CRO</td>
<td>Contract Research Organization</td>
</tr>
<tr>
<td>DRGs</td>
<td>Diagnosis Related Groups</td>
</tr>
<tr>
<td>ED</td>
<td>Erectile Dysfunction</td>
</tr>
<tr>
<td>FDI</td>
<td>Foreign Direct Investment</td>
</tr>
<tr>
<td>FIEs</td>
<td>Foreign Invested Enterprises</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practices</td>
</tr>
<tr>
<td>GDP</td>
<td>Gross Domestic Products</td>
</tr>
<tr>
<td>GLP</td>
<td>Good Laboratory Practices</td>
</tr>
<tr>
<td>GMP</td>
<td>Good Manufacturing Practices</td>
</tr>
<tr>
<td>GSP</td>
<td>Good Supply Practices</td>
</tr>
<tr>
<td>IFPMA</td>
<td>International Federation of Pharmaceutical Manufacturer Associations</td>
</tr>
<tr>
<td>JV</td>
<td>Joint Venture</td>
</tr>
<tr>
<td>M&amp;A</td>
<td>Merger and Acquisition</td>
</tr>
<tr>
<td>MIIT</td>
<td>Ministry of Industry and Information Technology</td>
</tr>
<tr>
<td>MOFCOM or MOC</td>
<td>Ministry of Commerce</td>
</tr>
<tr>
<td>MOF</td>
<td>Ministry of Finance</td>
</tr>
<tr>
<td>MOH</td>
<td>Ministry of Health</td>
</tr>
<tr>
<td>MoHRSS</td>
<td>Ministry of Human Resources and Social Security</td>
</tr>
<tr>
<td>NHFPC</td>
<td>National Health and Family Planning Commission</td>
</tr>
<tr>
<td>MNCs</td>
<td>Multinational pharmaceutical companies (<em>in the context of this guide</em>)</td>
</tr>
<tr>
<td>MR</td>
<td>Medical Representative</td>
</tr>
<tr>
<td>NBS</td>
<td>National Bureau of Statistics</td>
</tr>
<tr>
<td>NCGHSR</td>
<td>National Coordination Group for Healthcare System Reform</td>
</tr>
<tr>
<td>NDRC</td>
<td>National Development and Reform Commission</td>
</tr>
<tr>
<td>NHFPC</td>
<td>National Health and Family Planning Commission</td>
</tr>
<tr>
<td>OECD</td>
<td>Organization for Economic Co-operation and Development</td>
</tr>
<tr>
<td>OTC</td>
<td>Over the Counter</td>
</tr>
<tr>
<td>QA</td>
<td>Quality Assurance</td>
</tr>
<tr>
<td>QC</td>
<td>Quality Control</td>
</tr>
<tr>
<td>PRC</td>
<td>People’s Republic of China</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>Research and Development</td>
</tr>
<tr>
<td>RDPAC</td>
<td>R&amp;D-based Pharmaceutical Association Committee in China</td>
</tr>
<tr>
<td>SATCM</td>
<td>State Administration of Traditional Chinese Medicine</td>
</tr>
<tr>
<td>SDA</td>
<td>State Drug Administration</td>
</tr>
<tr>
<td>SFDA</td>
<td>State Food and Drug Administration of China (now China Food and Drug Administration or CFDA)</td>
</tr>
<tr>
<td>SIPO</td>
<td>State Intellectual Property Office</td>
</tr>
</tbody>
</table>
SMEI – Southern Medicine Economic Institute under the CFDA
SOE – State Owed Enterprise
SPAC – State Pharmaceutical Administration of China
STD – Sexually Transmitted Disease
TC – Therapeutic Class
TCM – Traditional Chinese Medicine
USTR – US Trade Representative

VAT – Value Added Tax
VC – Venture Capital
WM – Western medicine
WHO – World Health Organization
WTO – World Trade Organization
EXECUTIVE SUMMARY

Under the shadow of numerous challenges mostly stemmed from the troubled Chinese economy, regulatory shakeups, cost containment measures and healthcare reform turbulences, the Chinese pharmaceutical industry revenue growth slowed in 2015 to single digit (+9.1%) for the first time in the past decade, compared with 13.06% in 2014, 17.91% in 2013 and above 20% between 2007 and 2012, according to the China Pharmaceutical Guide 2016 (11th Edition) quoting official data.

While policy uncertainties continued to haunt Chinese pharma in 2015, industry analysts suggest that the sector’s revenue is stabilizing and long term sustainable growth continue to be anticipated as policy and business environments improve. The Chinese drug market (at retail price level) is reported by Southern Medicine Economic Institute under the CFDA (SMEI) to have grown 12.9% in 2015, slightly down from 13.4% in 2014, to reach CNY 1,407.0 billion.

SMEI data suggests that CAGRs of Chinese pharmaceutical industry output value and revenues in the 12th Five-Year Plan period (2011-2015) is expected to be 16.6% and 15.2% respectively. The Chinese pharmaceutical industry profit growth slowed in the period due to macro-economic changes, drug price reform and cost containment measures, compared with 37.6% in the previous 12th Five-Year Plan period (2006-2010). The profit growth of Chinese pharmaceutical industry is projected to reach 11.9% in 2015.

According to a report on the progress of healthcare reform by NHFPC Minister LI Ban to the 18th Session of the 12th National People's Congress in late 2015, the Chinese government made CNY 4 trillion fiscal investment into healthcare, including CNY 1.2 trillion from the central government between 2009 and 2014. 53 major healthcare policies covering public hospital reform, universal BMI system building and drug supply security had been introduced under the direction of the State Council's Leadership Group for Deepening Pharmaceutical and Health System Reform, which is made up by 20 central government agencies. The average life expectancy of Chinese people increased one year between 2010 and 2015. The share of personal out-of-pocket expenditures in total healthcare expenditures dropped to 31.99% in 2015 from 35.29% in 2010, the lowest in two decades.

There is no doubt the healthcare reform will go on with unchanged ambitions. In the reality, with tax and other revenues drying up and under increasing threat of BMI system deficit amid a slowing Chinese economy, local governments are pressured by both the central government and the public to do more with less. Despite its superficial goals, the healthcare reform has so far mostly been hijacked by containment of drug costs and no longer about improving efficiency and fixing structural flaws.

Pushed to the corner, both domestic and multinational drug companies are now at the brink of business bottomlines. However, the trend of irrational cost containment is expected to intensify further in 2016, with the central government upholding the radical healthcare reform experiment in Sanming City of Fujian Province as a model for national
reference.

On the front of drug pricing, however, there have been few indications that relevant Chinese government agencies are getting ready to introduce the planned uniform BMI payment price scheme anytime soon, although the deadline was set at the end of September by the 2015 healthcare reform plan of the State Council. Nonetheless, the NHFPC managed to move the trial for drug price negotiation mechanism forward last year.

In the meantime, Chinese president XI Jinping categorically demanded the government to implement “the toughest drug regulation” by setting the highest standards, exercising the most stringent regulation, imposing the stiffest penalties for violations and instituting the most serious accountabilities.

Other than introducing multiple rules and standards for drug quality control covering the full drug development, manufacturing and application process from laboratory to hospital (e.g. GLP, GCP, GMP and GSP), the CFDA has stepped up its random inspections in terms of both frequency and strength as well as raised efforts to combat corruption within relevant government agencies this year with numerous CFDA and NHFPC officials under investigations.

The reform goal declared by the agency was to turn the former "firefighting" approach of food and drug regulation into a new model that emphasizes on early risk screening and prevention through stepping up risk surveillance, supervisory samplings, onsite inspections, undercover investigations and administrative enforcements.

The recent CFDA’s move to elevate drug quality and reform drug approval system, though contradicted by other government agency’s preoccupation to slash drug costs, provides a ray of future hope for MNCs. With a better policed pharmaceutical industry aligned to rational cost structures, MNCs can expect to compete with domestic companies on a more leveled ground in future and fill market vacuum from exiting irregular players. The real questions are that, with the world’s largest population, what kind of healthcare solution and product mix China can and should get for merely 5%-6% of GDP? Is the country willing or able to pay more for better drugs and healthcare?

On the other hand, the Chinese pharma e-commerce sector has been brewing major revolutionary developments and is ready to fly pending official liberalization of online prescription drug sales. Under growing pressure from aggressive moves by e-commerce giants to enter drug distribution, leading pharmaceutical distributors rushed to reposition themselves to secure presence in the emerging pharma e-commerce sector in China.

The Chinese economy and its healthcare system are at crossroads and in transition again. This requires both domestic and MNC pharma companies to recalibrate their strategies and business models.

2015 inherited most old devils of the Chinese pharmaceutical business in prior years with no new fixes found. In the near future, the industry will continue to be challenged by rising uncertainties of the broad Chinese economy, more regulatory and healthcare reform turbulences and rising cost containment pressure. On the other hand, future prospects are
supported by upsides including a large and aging Chinese population plagued with surging health problems and chronic disease prevalence, increased government healthcare budgets and growing demands due to improved access to healthcare.

Local governments are set to put more price pressure on pharmaceutical companies in 2016, as they try to keep the public happy and at the same time balance the books of BMI programs, which are designed and funded to cover only essential healthcare needs, not to mention their fiscal crisis amid a slowing economy.

Despite short term difficulties, a few positive catalysts for long term prospects emerged last year, including 1) family planning policy liberalizations taking effect at the beginning of 2016 allow Chinese families to have second child, therefore creating substantially higher immediate and future demand for health and child care; and 2) recent crackdown on irregular clinical data and reform of the Chinese drug evaluation and approval system will lead to both short and long term benefits for MNCs.

For now, the short term outlook of Chinese pharmaceutical market remains mixed and blurred. But promising seeds are being sown today with hope of it turning into milk and honey one day. Nevertheless, most Chinese pharma industry observers agree that the market will keep on growing in the next few years, albeit at a slower rate.

Many drug company executives are still bullish about China's long-term growth prospects and drug spending is expected by IMS to reach as much as US$185 billion by 2018. But the short-term picture is proving less rosy, with reforms in the hospital sector impacting prescribing and price pressures increasing for most drugs. The company expects the overall Chinese pharmaceutical market to continue the existing slowing growth trend in the next few years. The company projects the market to rise around 9% CAGR between 2015 and 2019, compared with 16% CAGR between 2010 and 2014.

Separately, SMEI expects the Chinese pharmaceutical industry in output value and revenue to grow 11.3% and 8.7% to reach CNY 3,210.0 billion and CNY 2,904.4 billion in 2016. It forecasts the Chinese pharmaceutical industry output value and revenue to attain compound annual growth rates (CAGR) of 11-13% and 10.4% respectively in the 13th Five-Year Plan period (2016-2020), reaching CNY 4,840.0 billion and CNY 4,386.6 billion.

Industry experts recently pointed out that the fundamental aspects of the Chinese pharmaceutical industry has remained positive despite slowing growth, but they warned against a more complex Chinese marketplace in 2016. There will be lots of uncertainties, unbalances and frailty ahead. The future outlook is mixed, while most analysts agree that the market will keep on growing, but at a slower rate, continuing the trend which started two years ago.
**China Pharmaceutical Guide (Annual)**

*The Reference for Real World China Business*

This annually-updated Guide is the most *authoritative* and *comprehensive* reference and resource in English which is instrumental for executives to plan, implement, monitor and supervise pharmaceutical businesses in China

- Authored by James J. Shen, a veteran pharma executive and former managing editor of IMS China Update, who has 28 years of management experience in the Chinese pharma industry
- Prepared by the *Real Experts* for the *Real World Executives* to help them navigate through the complex and turbulent Chinese healthcare business environment
- Extensive coverage on China's pharma industry structure and market environment, regulatory framework, healthcare provision and financing, disease & drug consumption patterns, pharma sales, marketing & distribution, trends and opportunities, market entry strategies, case studies of successes and failures in six key areas of the Chinese pharma business, and profiles of leading MNC pharma players in China
- With comprehensive latest data and statistics, it is divided into four volumes. It contains over 1,200 pages & nearly 200 tables and charts
- Significantly expanded coverage in recent editions on more sub-sectors, outsourcing, clinical practices, regulatory updates on healthcare reform and drug policies, additional case studies, and latest market / health data updated annually

Please contact us for a *free* promotional PDF including the Table of Contents and Executive Summary, or download the above information online at our website: www.pharmachinaonline.com

---

**PRICING INFORMATION**

**WiCON | Pharma China (Journal Edition)**

<table>
<thead>
<tr>
<th>Annual Subscription</th>
<th>USD</th>
<th>RMB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single-user Print</td>
<td>1,800</td>
<td>13,000</td>
</tr>
<tr>
<td>Single-user PDF</td>
<td>1,800</td>
<td>13,000</td>
</tr>
<tr>
<td>Additional same-site user @ 40% off</td>
<td>1,080</td>
<td>7,800</td>
</tr>
<tr>
<td>Multi-user License (5 users)</td>
<td>5,400</td>
<td>39,000</td>
</tr>
<tr>
<td>Multi-user License (12 users)</td>
<td>10,800</td>
<td>78,000</td>
</tr>
</tbody>
</table>

**WiCON | Pharma China (Web Edition)**

<table>
<thead>
<tr>
<th>Annual Subscription</th>
<th>USD</th>
<th>RMB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single-user License</td>
<td>2,400</td>
<td>17,500</td>
</tr>
<tr>
<td>Multi-user License (5 users) for PDF</td>
<td>7,200</td>
<td>52,500</td>
</tr>
<tr>
<td>Multi-user License (12 users) for PDF</td>
<td>14,400</td>
<td>105,000</td>
</tr>
</tbody>
</table>

**Pharma China Gold Package**

*Single-user Gold Package receives the above two products (PDF or Print + Web Edition), plus Archives and Online Databases at a special price of US$2,950 or CNY 21,500. Contact us for multi-user licenses.*

**China Pharmaceutical Guide (Annually Updated)**

<table>
<thead>
<tr>
<th>USD</th>
<th>RMB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Print</td>
<td>4,200</td>
</tr>
<tr>
<td>Single-user PDF</td>
<td>4,100</td>
</tr>
<tr>
<td>Multi-user License (5 users) for PDF</td>
<td>12,300</td>
</tr>
<tr>
<td>Multi-user License (12 users) for PDF</td>
<td>24,600</td>
</tr>
</tbody>
</table>

**Pharma China Platinum Package**

*China Pharmaceutical Guide (latest edition) plus Pharma China Gold Package at a special price of US$5,800 or CNY 42,000 (Single-user). Contact us for multi-user licenses and for customized quotes and latest offers.*
**WiCON | Pharma China**  
(Monthly Journal Edition)  

**Written by Executives for Executives**

Written by veteran pharmaceutical executives, **WiCON | Pharma China** is a monthly business journal (in print and PDF) that provides latest news, inside stories, in-depth analysis of issues and trends, and expert insights on China's pharmaceutical industry and market. It is published by WiCON, former co-publisher of IMS China Update.

Going beyond the traditional factual news coverage of IMS China Update, **WiCON | Pharma China** brings trade news reporting up to a new level combining strength of traditional news coverage with the power of in-depth analysis, expert opinions, editorials and exclusive interviews.

It is often used as a third party source to validate in-house or externally sourced information.

**Coverage of WiCON | Pharma China include:**

- Latest News, Analysis and Commentaries
- Editorials and analytical articles from Our Chief Editor, James J. Shen and editorial team
- Featured Articles from Senior Pharmaceutical Industry Executives / Experts
- Exclusive Interviews with Senior Chinese Pharma Industry Executives / Officials
- Relevant Pharmaceutical and Health Statistics
- Exclusive Info Releases from Premium Data Providers

**WiCON | Pharma China**  
(Web Edition)  

**Be in the Driver Seat of China Business**

**WiCON | Pharma China** (Web Edition) brings China healthcare news to you as and when they happen. Our subscribers can access the online news service at our website anytime and anywhere. Subscribers receive a weekly e-bulletin, with summaries of important news in the week and links to full stories.

The entire content of **WiCON | Pharma China** (Journal Edition) is available through **WiCON | Pharma China** (Web Edition).

The service has following coverage:

**Comprehensive News Coverage**


**Feature Articles**

Editorials, Commentaries and Insights, Expert Opinions, Interviews, and Case Studies

**General Information on Pharma Industry**

**WiCON | Pharma China** (Web Edition) provides a powerful feature that allows users to search current news and commentaries, as well as a vast volume of back data via keywords.

Nearly 30% discounts for combined orders with **WiCON | Pharma China** (Journal Edition) and China Pharmaceutical Guide (as gold and platinum packages).

Please visit [www.pharmachinaonline.com](http://www.pharmachinaonline.com) to preview **WiCON | Pharma China** (Web Edition)

All our clients receive via e-mail, with our compliments, the Premium Edition of **Pharma China Weekly e-Alert** which summaries the top Chinese Pharma news each week.

**WiCON | Pharma China** developed the following databases to provide international pharma companies with continuously-updated intelligence on a number of important aspects of the Chinese pharma business.

**Deals, Disputes & IPO Monitor**

This database monitors and records agreements, transactions and events in the areas of OEM, licensing, R&D, M&A, lawsuits and disputes, and IPOs (mainly overseas) in the Chinese pharmaceutical industry. This proprietary database is developed using industry data **WiCON** accumulated in the past two decades. The database can be searched by event or transaction type, company and keywords.

**Regulatory Monitor**

This proprietary database monitors the development of the Chinese drug regulatory regime and records historical and current regulations issued by various regulatory authorities in China. An expert summary is provided for all laws and regulations recorded with important facts, eg. issuance agency and effective date.

Laws and regulations are also categorized by type (eg. law, regulations, rule or notice), issuance agency and regulatory areas. The database can be searched by keywords, type, issuance agency and regulatory area.

**New Drug R&D Monitor**

The database contains information on new drug products under development in China and monitors latest Chinese R&D developments reported globally. The database can be searched by keywords, therapeutic class, product type and regulatory status, and contains additional information including developer names and a summary of research and regulatory status.

**Note:** The Online Database Edition is intended as an added value product for existing Pharma China gold & platinum package subscribers. It is not sold separately.

**WiCON | Pharma China** (Online Database Edition)  
Intelligent and Creative Solutions!